<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1" xml:lang="EN"
    xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <front>
        <journal-meta>
            <journal-id journal-id-type="hwp">ALMED</journal-id>
            <journal-id journal-id-type="pmc">ALMED</journal-id>
            <journal-id journal-id-type="publisher-id">ALMED</journal-id>
            <journal-title-group>
                <journal-title>Blood, The Journal of the American Society of Hematology</journal-title>
                <abbrev-journal-title abbrev-type="full">Blood</abbrev-journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0006-4971</issn>
            <issn pub-type="epub">1528-0020</issn>
            <publisher>
                <publisher-name>American Society of Hematology</publisher-name>
                <publisher-loc>Washington, DC</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">10921</article-id>
            <article-id pub-id-type="doi">10921</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Regular Article</subject>
                </subj-group>
                <subj-group subj-group-type="leader">
                    <subject>Lymphoid Neoplasia</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>FOXP1 expression is a prognostic biomarker in follicular lymphoma
                    treated with rituximab-containing chemotherapy</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3125-0494</contrib-id>
                    <name>
                        <surname>Mot<!--Q1:
                            Please check and confirm author names. -->tok</surname>
                        <given-names>Anja</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1">1</xref>
                    <xref ref-type="aff" rid="aff2">2</xref>
                    <xref ref-type="aff" rid="aff3">3</xref>
                    <xref ref-type="fn" rid="fn1">&#x2a;</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Jurinovic</surname>
                        <given-names>Vindi</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff4">4</xref>
                    <xref ref-type="aff" rid="aff5">5</xref>
                    <xref ref-type="fn" rid="fn1">&#x2a;</xref>
                </contrib>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9364-9391</contrib-id>
                    <name>
                        <surname>Farinha</surname>
                        <given-names>Pedro</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1">1</xref>
                    <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Rosenwald</surname>
                        <given-names>Andreas</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2461-8070</contrib-id>
                    <name>
                        <surname>Leich</surname>
                        <given-names>Ellen</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7990-6793</contrib-id>
                    <name>
                        <surname>Ott</surname>
                        <given-names>German</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Horn</surname>
                        <given-names>Heike</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff6">6</xref>
                    <xref ref-type="aff" rid="aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Klapper</surname>
                        <given-names>Wolfram</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Boesl</surname>
                        <given-names>Michael</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Hiddemann</surname>
                        <given-names>Wolfgang</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9842-9750</contrib-id>
                    <name>
                        <surname>Steidl</surname>
                        <given-names>Christian</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1">1</xref>
                    <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1361-7531</contrib-id>
                    <name>
                        <surname>Connors</surname>
                        <given-names>Joseph M.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Sehn</surname>
                        <given-names>Laurie H.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2610-5690</contrib-id>
                    <name>
                        <surname>Gascoyne</surname>
                        <given-names>Randy D.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1">1</xref>
                    <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Hoster</surname>
                        <given-names>Eva</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff4">4</xref>
                    <xref ref-type="aff" rid="aff5">5</xref>
                    <xref ref-type="fn" rid="fn1">&#x2a;</xref>
                </contrib>
                <contrib contrib-type="author">
                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0987-7373</contrib-id>
                    <name>
                        <surname>Weigert</surname>
                        <given-names>Oliver</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff4">4</xref>
                    <xref ref-type="fn" rid="fn1">&#x2a;</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0287-7124</contrib-id>
                    <name>
                        <surname>Kridel</surname>
                        <given-names>Robert</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff9">9</xref>
                    <xref ref-type="fn" rid="fn1">&#x2a;</xref>
                </contrib>
                <aff id="aff1"><label>1</label>Centre for Lymphoid Cancer, BC Cancer Agency,
                    Vancouver, BC, Canada; </aff>
                <aff id="aff2"><label>2</label>Department of Pathology and Laboratory Medicine,
                    University of British Columbia, Vancouver, BC, Canada; </aff>
                <aff id="aff3"><label>3</label>Institute of Pathology, University of W&#xfc;rzburg
                    and Comprehensive Cancer Centre Mainfranken, W&#xfc;rzburg, Germany; </aff>
                <aff id="aff4"><label>4</label>Medical Department III, University Hospital and </aff>
                <aff id="aff5"><label>5</label>Institute for Medical Information Processing,
                    Biometry and Epidemiology, Ludwig Maximilians University Munich, Munich,
                    Germany; </aff>
                <aff id="aff6"><label>6</label>Department of Clinical Pathology,
                    Robert-Bosch-Hospital and Dr. Margarete Fischer-Bosch Institute of Clinical
                    Pharmacology, Stuttgart, Germany; </aff>
                <aff id="aff7"><label>7</label>University of T&#xfc;bingen, T&#xfc;bingen, Germany; </aff>
                <aff id="aff8"><label>8</label>Department of Pathology, Hematopathology Section and
                    Lymph Node Registry, University Kiel, Kiel, Germany; and </aff>
                <aff id="aff9"><label>9</label>Division of Medical Oncology and Hematology, Princess
                    Margaret Cancer Centre &#x2013; University Health Network, Toronto, ON, Canada</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="equal" id="fn1">
                    <label>&#x2a;</label>
                    <p id="sec-p-001">A.M., V.J., E.H., O.W., and R.K. contributed equally to this study.</p>
                </fn>
                <corresp id="cor1"><label>&#x2a;</label>Address for Correspondence: Test A. Author,
                    PhD, Assistant Professor, University of Tennessee Health Science Center, Dept of
                    Ophthalmology, Hamilton Eye Institute, 930 Madison Ave, Suite 722A, Memphis, TN
                    38163, Phone 901-448-1910, Fax 901-448-5028, <email
                        xlink:href="dmahendren@tnqsoftware.co.in">dmahendren@tnqsoftware.co.in</email></corresp>
            </author-notes>
            <pub-date pub-type="ppub">
                <day>00</day>
                <month>00</month>
                <year>2017</year>
            </pub-date>
            <pub-date pub-type="epreprint">
                <day>09</day>
                <month>11</month>
                <year>2017</year>
            </pub-date>
            <volume>00</volume>
            <issue>00</issue>
            <fpage>00</fpage>
            <lpage>00</lpage>
            <history>
                <date date-type="received">
                    <day>03</day>
                    <month>08</month>
                    <year>2017</year>
                </date>
                <date date-type="accepted">
                    <day>27</day>
                    <month>10</month>
                    <year>2017</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>&#xa9; 2017 by The American Society of Hematology</copyright-statement>
                <copyright-year>2017</copyright-year>
            </permissions>
            <self-uri xlink:title="pdf" xlink:href="blood-2017-08-799080.pdf" />
            <self-uri xlink:role="icon" xlink:href="blood799080_thumb.jpg" />
            <abstract abstract-type="executive-summary">
                <title>Key Points</title>
                <p id="sec-p-002">
                    <list list-type="bullet">
                        <list-item>
                            <p id="sec-p-003">High expression of FOXP1 predicts adverse FFS in patients with FL
                                treated with immunochemotherapy.</p>
                        </list-item>
                        <list-item>
                            <p id="sec-p-004">FOXP1 high and low expressors differ in specific gene mutations and
                                gene expression changes.</p>
                        </list-item>
                    </list>
                </p>
            </abstract>
            <abstract>
                <p id="sec-p-005">Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous
                    disease, yet prognostication relies predominantly on clinical tools. We recently
                    demonstrated that integration of mutation status of 7 genes, including <italic>
                    EZH2</italic> and <italic>MEF2B,</italic> improves risk stratification. We mined
                    gene expression data to uncover genes that are differentially expressed in <italic>
                    EZH2</italic>- and <italic>MEF2B</italic>-mutated cases. We focused on <italic>
                    FOXP1</italic> and assessed its protein expression by immunohistochemistry (IHC)
                    in 763 tissue biopsies. For outcome correlation, a population-based training
                    cohort of 142 patients with FL treated with rituximab, cyclophosphamide,
                    vincristine, and prednisone, and a clinical trial validation cohort comprising
                    395 patients treated with cyclophosphamide, doxorubicin, vincristine, and
                    prednisone (CHOP) <sup>&#x2b;/&#x2212;</sup> rituximab were used. We found FOXP1
                    to be significantly downregulated in both <italic>EZH2</italic>- and <italic>
                    MEF2B</italic>-mutated cases. By IHC, 76 specimens in the training cohort (54%)
                    had high FOXP1 expression (&#x3e;10%), which was associated with reduced 5-year
                    failure-free survival (FFS) rates (55% vs 70%). In the validation cohort, high
                    FOXP1 expression status was observed in 248 patients (63%) and correlated with
                    significantly shorter FFS in patients treated with <italic>R</italic>-CHOP
                    (hazard ratio [HR], 1.95; <italic>P</italic> &#x3d; .017) but not in patients
                    treated with CHOP (HR, 1.15; <italic>P</italic> &#x3d; .44). The impact of high
                    FOXP1 expression on FFS in immunochemotherapy-treated patients was additional to
                    the Follicular Lymphoma International Prognostic Index. High FOXP1 expression
                    was associated with distinct molecular features such as <italic>TP53</italic>
                    mutations, expression of IRF4, and gene expression signatures reminiscent of
                    dark zone germinal center or activated B cells. In summary, FOXP1 is a
                    downstream phenotypic commonality of gene mutations and predicts outcome
                    following rituximab-containing regimens.</p>
            </abstract>
            <abstract abstract-type="graphical">
                <title>Visual Abstract</title>
                <p id="sec-p-006">
                    <fig id="absf1" position="float">
                        <image src="../images/LSA-99999_absf1.tif" width="0.82\linewidth" />
                    </fig>
                </p>
            </abstract>
            <counts>
                <page-count count="0" />
            </counts>
        </article-meta>
    </front>
    <body>
        <sec id="sec-001" sec-type="intro">
            <title>Introduction</title>
            <p id="sec-p-007">Follicular lymphoma (FL) is the second most common subtype of lymphoma,<sup>
                    <xref ref-type="bibr" rid="B1">1</xref>
                </sup> usually
                characterized by a slowly progressive disease course.<sup>
                    <xref ref-type="bibr" rid="B2">2</xref>
                </sup> However, most
                patients with FL present with advanced-stage disease and are considered to have an
                incurable illness with current standard immunochemotherapy regimens, because they
                will eventually experience progression and/or transformation to aggressive
                histological status. The translocation t(14;18)(q32;q21), resulting in the
                juxtaposition of the <italic>BCL2</italic> gene under the control of the <italic>IGH</italic>
                promoter, is a genetic hallmark of FL, because it is present in 75% to 90% of cases.<sup><xref
                        ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref></sup>
                It has long been recognized that this translocation is insufficient for
                lymphomagenesis and that additional genetic alterations are required to develop
                overt FL. <sup><xref ref-type="bibr" rid="B5">5</xref><xref ref-type="bibr" rid="B6" /><xref
                        ref-type="bibr" rid="B7" />-<xref ref-type="bibr" rid="B8">8</xref></sup>
                During the last few years, the advent of next-generation sequencing technology has
                led to dramatic improvements in our understanding of the genetics that underlie
                pathogenesis and disease evolution.<sup><xref ref-type="bibr" rid="B9">9</xref><xref
                        ref-type="bibr" rid="B10" /><xref ref-type="bibr" rid="B11" /><xref
                        ref-type="bibr" rid="B12" /><xref ref-type="bibr" rid="B13" />-<xref
                        ref-type="bibr" rid="B14">14</xref></sup> Of particular relevance are
                genetic aberrations of histone modifiers and chromatin remodeling genes, which are
                among the most frequently mutated genes in FL and diffuse large B-cell lymphoma
                (DLBCL).<sup><xref ref-type="bibr" rid="B14">14</xref><xref ref-type="bibr"
                        rid="B15" /><xref ref-type="bibr" rid="B16" />-<xref ref-type="bibr"
                        rid="B17">17</xref></sup><disp-formula id="eq1">
                    <label>[1]</label>
                    <graphic xlink:href="dmd.116.072397eq1" />
                </disp-formula>Although
                FL is recognized as a clinically and molecularly highly heterogeneous disease,
                prognostication relies predominantly on clinical tools,<sup><xref ref-type="bibr"
                        rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref></sup> and
                there is currently no consensus strategy that allows for risk-based treatment
                stratification <inline-formula id="inline-eq-001">
                    <inline-graphic xlink:href="advances000943inf1" />
                </inline-formula>.
                We have recently demonstrated that integration of the mutation status of 7 genes <inline-formula id="inline-eq-002">
                    <mml:math id="i31">
                        <mml:mrow>
                            <mml:mi>&#x3c7;</mml:mi>
                            <mml:mo>&#x2009;</mml:mo>
                            <mml:mo>&#x3c;</mml:mo>
                            <mml:mo>&#x2009;</mml:mo>
                            <mml:mn>1</mml:mn>
                        </mml:mrow>
                    </mml:math>
                </inline-formula>
                (including <italic>EZH2</italic> and <italic>MEF2B)</italic> into a combined
                clinic-genetic risk model<sup>
                    <xref ref-type="bibr" rid="B18">18</xref>
                </sup> improves risk
                stratification and represents a promising approach to identify a subset of patients
                at highest risk of treatment failure.<sup>
                    <xref ref-type="bibr" rid="B20">20</xref>
                </sup> In particular, <italic>
                EZH2</italic> mutations were associated with longer failure-free survival (FFS) in 2
                independent cohorts of patients receiving immunochemotherapy, a finding that was
                recently validated in 2 additional series.<sup><xref ref-type="bibr" rid="B21">21</xref>
                ,<xref ref-type="bibr" rid="B22">22</xref></sup> EZH2 functions as a histone
                methyltransferase and is a component of the Polycomb repressive complex 2, mediating
                repression of gene expression by methylation of histone H3 on lysine 27 residues.<sup><xref
                        ref-type="bibr" rid="B23">23</xref><xref ref-type="bibr" rid="B24" /><xref
                        ref-type="bibr" rid="B25" />-<xref ref-type="bibr" rid="B26">26</xref></sup> <italic>
                EZH2</italic> is frequently mutated in malignant lymphomas, and gain-of-function
                hotspot mutations (mostly affecting amino acid position Y646) have been identified
                in the germinal center B-cell&#x2013;like (GCB) subtype of DLBCL and in FL.<sup><xref
                        ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B27">27</xref><xref
                        ref-type="bibr" rid="B28" />-<xref ref-type="bibr" rid="B29">29</xref></sup>
                MEF2 proteins belong to a transcription factor family that has been shown to play a
                central role in the development of mesenchymal tissue, the central nervous system,
                and lymphoid cells.<sup>
                    <xref ref-type="bibr" rid="B30">30</xref>
                </sup> Virtually all <italic>
                MEF2B</italic> mutations detected in FL occur in the <italic>N</italic>-terminal
                domains, which are involved in DNA binding and homodimerization.<sup><xref
                        ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup><disp-formula
                    id="eq2">
                    <mml:math id="me2" display="block">
                        <mml:mrow>
                            <mml:mi>J</mml:mi>
                            <mml:mo>&#x3d;</mml:mo>
                            <mml:mfrac>
                                <mml:mn>1</mml:mn>
                                <mml:mrow>
                                    <mml:msub>
                                        <mml:mi>N</mml:mi>
                                        <mml:mrow>
                                            <mml:mtext>pixels</mml:mtext>
                                        </mml:mrow>
                                    </mml:msub>
                                </mml:mrow>
                            </mml:mfrac>
                            <mml:mstyle displaystyle="true">
                                <mml:munder>
                                    <mml:mo>&#x2211;</mml:mo>
                                    <mml:mrow>
                                        <mml:mi>i</mml:mi>
                                        <mml:mo>,</mml:mo>
                                        <mml:mi>j</mml:mi>
                                    </mml:mrow>
                                </mml:munder>
                                <mml:mrow>
                                    <mml:mi>&#x3c3;</mml:mi>
                                    <mml:mrow>
                                        <mml:mo>(</mml:mo>
                                        <mml:mrow>
                                            <mml:mi>i</mml:mi>
                                            <mml:mo>,</mml:mo>
                                            <mml:mi>j</mml:mi>
                                        </mml:mrow>
                                        <mml:mo>)</mml:mo>
                                    </mml:mrow>
                                </mml:mrow>
                            </mml:mstyle>
                            <mml:mo>.</mml:mo>
                        </mml:mrow>
                    </mml:math>
                    <label>(2)</label>
                </disp-formula>The goals of the current study
                were to identify putative transcriptional targets of EZH2 and MEF2B and to assess
                their relevance for prognostication and molecular subtyping. We focused on <italic>
                FOXP1</italic> because its expression was significantly downregulated in <italic>
                EZH2</italic>-mutated cases from 4 independent studies, as well as in <italic>MEF2B</italic>-mutated
                cases.<sup><xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">
                21</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">
                29</xref></sup> We leveraged 2 large independent cohorts to assess the relationship
                between FOXP1 expression and outcome. In addition, we performed in-depth molecular
                characterization to answer the question whether select genotypic and phenotypic
                alterations are associated with FOXP1 expression. In aggregate, our findings
                illustrate the predictive value of FOXP1 expression in FL, and open new avenues for
                pursuing distinct therapeutic targeting of vulnerabilities associated with FOXP1
                expression status.<disp-formula id="eq3">
                    <mml:math id="me1" display="block">
                        <mml:mrow>
                            <mml:mi>&#x3c3;</mml:mi>
                            <mml:mrow>
                                <mml:mo>(</mml:mo>
                                <mml:mrow>
                                    <mml:mi>i</mml:mi>
                                    <mml:mo>,</mml:mo>
                                    <mml:mi>j</mml:mi>
                                </mml:mrow>
                                <mml:mo>)</mml:mo>
                            </mml:mrow>
                            <mml:mo>&#x3d;</mml:mo>
                            <mml:mfrac>
                                <mml:mn>1</mml:mn>
                                <mml:mi>N</mml:mi>
                            </mml:mfrac>
                            <mml:mstyle displaystyle="true">
                                <mml:munder>
                                    <mml:mo>&#x2211;</mml:mo>
                                    <mml:mrow>
                                        <mml:mtext>particles</mml:mtext>
                                    </mml:mrow>
                                </mml:munder>
                                <mml:mrow>
                                    <mml:mrow>
                                        <mml:mo>(</mml:mo>
                                        <mml:mrow>
                                            <mml:mrow>
                                                <mml:mi>u</mml:mi>
                                                <mml:mo>/</mml:mo>
                                                <mml:mi>U</mml:mi>
                                            </mml:mrow>
                                        </mml:mrow>
                                        <mml:mo>)</mml:mo>
                                    </mml:mrow>
                                </mml:mrow>
                            </mml:mstyle>
                            <mml:mo>,</mml:mo>
                        </mml:mrow>
                    </mml:math>
                    <label>(1)</label>
                </disp-formula></p>
        </sec>
        <sec id="sec-002" sec-type="methods">
            <title>Methods</title>
            <sec id="sec-003">
                <title>Patients and tissue biopsy materials</title>
                <p id="sec-p-008">In total, we analyzed tissue biopsies from 763 patients with FL in this study.
                    The training cohort consisted of 142 patients who had been treated with
                    rituximab, cyclophosphamide, vincristine, and prednisone (<italic>R</italic>-CVP)
                    at the BC Cancer Agency (BCCA) between 2003 and 2009. From 2006 onward,
                    maintenance therapy with rituximab was given to those patients achieving a
                    partial or a complete remission. Patients were retrospectively selected from the
                    database of the Centre for Lymphoid Cancer at BCCA. The validation cohort
                    consisted of 395 patients with advanced-stage FL who were prospectively included
                    into trials from the German Low-Grade Lymphoma Study Group (GLSG). Patients were
                    considered eligible for this study if they had been treated with
                    cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as part of the
                    GLSG1996 trial,<sup>
                        <xref ref-type="bibr" rid="B32">32</xref>
                    </sup> or CHOP
                    with rituximab (<italic>R</italic>-CHOP) or without rituximab as part of the
                    GLSG2000 trial.<sup>
                        <xref ref-type="bibr" rid="B33">33</xref>
                    </sup> In the
                    latter trial, patients aged 60 years or younger achieving at least a partial
                    remission could be randomly assigned to either total body irradiation, high-dose
                    chemotherapy, and autologous stem cell transplantation (ASCT), or to maintenance
                    therapy with interferon-&#x3b1;.<sup>
                        <xref ref-type="bibr" rid="B33">33</xref>
                    </sup> In
                    addition, for exploratory analyses, we used specimens from 350 patients with
                    patients from BCCA, 124 of which overlapped with the aforementioned training
                    cohort. All tissue biopsies were arranged in previously constructed tissue
                    microarrays and were used for evaluation of FOXP1 protein expression by
                    immunohistochemistry (IHC). All research described herein was approved by the
                    respective Research Ethics Boards.<disp-formula id="eq4">
                        <mml:math id="me1" display="block">
                            <mml:mrow>
                                <mml:mi>&#x3c3;</mml:mi>
                                <mml:mrow>
                                    <mml:mo>(</mml:mo>
                                    <mml:mrow>
                                        <mml:mi>i</mml:mi>
                                        <mml:mo>,</mml:mo>
                                        <mml:mi>j</mml:mi>
                                    </mml:mrow>
                                    <mml:mo>)</mml:mo>
                                </mml:mrow>
                                <mml:mo>&#x3d;</mml:mo>
                                <mml:mfrac>
                                    <mml:mn>1</mml:mn>
                                    <mml:mi>N</mml:mi>
                                </mml:mfrac>
                                <mml:mstyle displaystyle="true">
                                    <mml:munder>
                                        <mml:mo>&#x2211;</mml:mo>
                                        <mml:mrow>
                                            <mml:mtext>particles</mml:mtext>
                                        </mml:mrow>
                                    </mml:munder>
                                    <mml:mrow>
                                        <mml:mrow>
                                            <mml:mo>(</mml:mo>
                                            <mml:mrow>
                                                <mml:mrow>
                                                    <mml:mi>u</mml:mi>
                                                    <mml:mo>/</mml:mo>
                                                    <mml:mi>U</mml:mi>
                                                </mml:mrow>
                                            </mml:mrow>
                                            <mml:mo>)</mml:mo>
                                        </mml:mrow>
                                    </mml:mrow>
                                </mml:mstyle>
                                <mml:mo>,</mml:mo>
                            </mml:mrow>
                        </mml:math>
                        <label>(4)</label>
                    </disp-formula></p>
            </sec>
            <sec id="sec-004">
                <title>IHC and Fluorescence in Situ Hybridization</title>
                <p id="sec-p-009">IHC for FOXP1 was performed on tissue microarrays using a monoclonal mouse
                    antibody against FOXP1 (clone JC12, ThermoFisher Scientific). IHC staining was
                    performed on a Ventana BenchMark XT system (Ventana Medical Systems), and slides
                    were independently evaluated by 2 hematopathologists (A.M., P.F.). The
                    percentage of tumor cells stained was recorded in 10% increments. All cases of
                    the training cohort were scored again on a multiheaded microscope to derive 1
                    consensus score per case for cutoff determination. Discrepant cases (ie,
                    positive vs negative) in the validation cohort were subjected to re-review and
                    discussion of the cases on a multiheaded microscope until consensus was reached.
                    In addition, the intensity of staining was recorded (weak, moderate, or strong).
                    As a reference point for the assessment of staining intensity in the malignant
                    cell population, we used small, reactive T cells in the tumor microenvironment,
                    which typically display moderate to strong nuclear staining. We did not take
                    staining intensity into consideration for outcome analyses.</p>
            </sec>
            <sec id="sec-005">
                <title>Gene mutations and GSEA</title>
                <p id="sec-p-010">Gene mutations and Illumina Whole-Genome DASL gene expression data were generated
                    and analyzed as previously described.<sup><xref ref-type="bibr" rid="B11">11</xref>
                    ,<xref ref-type="bibr" rid="B20">20</xref></sup> For gene expression analysis,
                    we collapsed genes with multiple probes into 1 value per sample using the WGCNA
                    R software package (version 1.51).<sup>
                        <xref ref-type="bibr" rid="B34">34</xref>
                    </sup>
                    Activated B-cell (ABC), GCB, and NF-&#x3ba;B signatures were obtained from the
                    Web companion of Shaffer et al.<sup>
                        <xref ref-type="bibr" rid="B35">35</xref>
                    </sup> We
                    derived signatures from normal GC dark and light zone cells using the data set
                    from Victora et al (NCBI&#x2019;s Gene Expression Omnibus data set GSE38697).<sup>
                        <xref ref-type="bibr" rid="B36">36</xref>
                    </sup> Gene
                    expression data were quantile normalized with use of the affy R package (version
                    1.52.0),<sup>
                        <xref ref-type="bibr" rid="B37">37</xref>
                    </sup> and
                    differential gene expression changes were determined with use of the limma R
                    package (version 3.30.13).<sup>
                        <xref ref-type="bibr" rid="B38">38</xref>
                    </sup> Genes
                    were deemed to be differentially expressed if <italic>P</italic> value &#x3c;
                    .01 and absolute(log2(fold-change)) &#x3e; 1. In order to test the association
                    of gene mutations with FOXP1 expression, we performed pairwise Fisher&#x27;s
                    exact tests, with resulting <italic>P</italic> values adjusted for false
                    discovery (fdr &#x3c; 0.1). We performed gene set enrichment analysis (GSEA)
                    using the Java-based Desktop application of GSEA (version 2.2.4).<sup>
                        <xref ref-type="bibr" rid="B39">39</xref>
                    </sup> In order
                    to ascertain deregulated pathways in low and high FOXP1 expressors, we performed
                    differential gene expression analysis in extremes of FOXP1 expression (n &#x3d;
                    58 with 0% FOXP1 expression and n &#x3d; 30 with &#x3e;50% FOXP1 expression). We
                    used a <italic>P</italic> cutoff value of .05 for input into a custom R Reactome
                    FI Cytoscape plugin wrapper.</p>
            </sec>
            <sec id="sec-006">
                <title>Statistical analysis</title>
                <p id="sec-p-011">To differentiate cases with high vs low FOXP1 expression, we chose the cutoff
                    point that maximized the log-rank test statistic for FFS in the training cohort.
                    The primary end point for this study was FFS, defined as the time between start
                    of first induction treatment to either stable disease after first induction,
                    progression, or death from any cause. For patients with stable disease after
                    induction, progression was counted at the time of initiation of new treatment in
                    the BCCA cohort, and at the time of documentation of stable disease that was
                    considered an indication for second-line treatment in the GLSG cohort. In the
                    validation cohort, patients receiving ASCT were censored for FFS at the stem
                    cell reinfusion date. In a sensitivity analysis, we evaluated FFS without
                    censoring for ASCT. Based on a prior attempt to validate the prognostic value of
                    FOXP1 in the validation cohort, we performed a power calculation to determine
                    whether enough events had been observed. Given 191 observed events for FFS, the
                    power to detect a hazard ratio (HR) of at least 1.81 as observed in the training
                    cohort was 98%. The effect of FOXP1 expression on FFS in the validation cohort
                    was estimated with use of Cox regression analysis, also adjusting for binary
                    Follicular Lymphoma International Prognostic Index (FLIPI; high vs
                    low/intermediate) or for FLIPI factors. To account for different outcome
                    according to use of rituximab in addition to CHOP during induction, we performed
                    a formal interaction analysis of rituximab use and FOXP1 expression. We
                    determined associations between categorical variables using Fisher&#x2019;s
                    exact test or the &#x3c7;<sup>2</sup> test for variables with more than 2
                    categories. We performed all analyses using R.<sup>
                        <xref ref-type="bibr" rid="B40">40</xref>
                    </sup></p>
            </sec>
        </sec>
        <sec id="sec-007" sec-type="results">
            <title>Results</title>
            <sec id="sec-008">
                <title><italic>FOXP1</italic> messenger RNA expression is downregulated in <italic>
                    EZH2-</italic> and <italic>MEF2B</italic>-mutated cases</title>
                <p id="sec-p-012">Because <italic>EZH2</italic> mutations lead to increased repression of gene
                    expression, we focused on genes that had lower expression in <italic>EZH2</italic>-mutated
                    vs <italic>EZH2</italic>-wild-type cases. In our own gene expression data set<sup>
                        <xref ref-type="bibr" rid="B20">20</xref>
                    </sup> and
                    those from 3 additional studies,<sup><xref ref-type="bibr" rid="B21">21</xref>,<xref
                            ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref></sup>
                    3 genes (<italic>FOXP1</italic>, <italic>TCL1A,</italic> and <italic>RASGRP2</italic>)
                    were consistently downregulated in <italic>EZH2</italic>-mutated cases (<xref
                        ref-type="fig" rid="F1">Figure 1A-B</xref>). We concentrated on the forkhead
                    transcription factor FOXP1 because assessment of its protein expression by IHC
                    is widely available and has prognostic value in DLBCL.<sup>
                        <xref ref-type="bibr" rid="B41">41</xref>
                    </sup> We had
                    previously shown that <italic>MEF2B</italic> mutations are enriched in m7-FLIPI
                    low cases, similar to <italic>EZH2</italic> mutations.<sup>
                        <xref ref-type="bibr" rid="B20">20</xref>
                    </sup> <italic>
                    FOXP1</italic> expression was also significantly downregulated in cases with
                    mutated <italic>MEF2B</italic> (<xref ref-type="fig" rid="F1">Figure 1B</xref>).
                    In addition, we observed a highly significant overlap between genes
                    downregulated in <italic>EZH2-</italic> and <italic>MEFB2</italic>-mutated
                    cases, suggesting that the transcriptional footprints of these 2 genes mediate
                    similar biological programs (<italic>P</italic> &#x3d; 2.78 &#xd7; 10<sup>
                    &#x2212;7</sup>; supplemental Table 1, available on the <italic>Blood</italic>
                    Web site). Given the aforementioned associations, we hypothesized that high
                    expression of FOXP1 correlates with adverse FFS.</p>
                <fig id="fig-F1" placement="[htbp]">
                    <label>Figure 1.</label>
                    <caption>
                        <p id="sec-p-013"><bold><italic>EZH2</italic> mutations are associated with transcriptional
                            regulation of FOXP1.</bold> (A) Venn diagram displaying the respective
                            overlaps of downregulated genes according to <italic>EZH2</italic>
                            mutation status. Three genes (<italic>FOXP1, TCL1A,</italic> and <italic>
                            RASGRP2</italic>) were found to be consistently downregulated in <italic>
                            EZH2</italic>-mutant cases. (B) Assessment of FOXP1 messenger RNA
                            transcript levels showed significant downregulation of FOXP1 expression
                            in <italic>EZH2</italic>- and <italic>MEF2B</italic>-mutated cases
                            compared with wild-type. (C) Depicted are hematoxylin and eosin (HE;
                            left) and FOXP1 IHC (right) of an <italic>EZH2-</italic>unmutated and <italic>
                            EZH2</italic>-mutated case, respectively. Original magnification:
                            200&#xd7; (HE), 100&#xd7; (FOXP1 IHC; inserts 400&#xd7;). (D) Stacked
                            bar plot showing the distribution of percentages of positively stained
                            tumor cells and the staining intensity. Numbers on the y-axis represent
                            the number of cases with the respective pattern.</p>
                    </caption>
                    <image src="../images/LSA-99999_fig1.tif" width="0.82\linewidth" />
                </fig>
            </sec>
            <sec id="sec-009">
                <title>FOXP1 staining in the training cohort</title>
                <p id="sec-p-014">The training cohort consisted of 142 FL specimens from patients treated with <italic>
                    R</italic>-CVP, with or without rituximab maintenance, and in which FOXP1 IHC (<xref
                        ref-type="fig" rid="F1">Figure 1C</xref>) was evaluable. Clinical
                    characteristics are shown in supplemental Table 2. The distribution of
                    percentage and intensity of staining is shown in <xref ref-type="fig" rid="F1">Figure
                    1D</xref>. The cutoff value that best separated favorable from unfavorable FFS
                    was determined to be &#x3e;10% tumor cells expressing FOXP1 based on the
                    log-rank test statistic (<italic>P</italic> &#x3d; .035). Based on this
                    threshold, specimens from 76 patients in the training cohort (54%) had high
                    FOXP1 expression. Clinical risk factors were similarly distributed among
                    patients with FOXP1 high vs low expression, with the exception that elevated
                    levels of lactate dehydrogenase (LDH) were more commonly observed in patients
                    with high FOXP1 expression (27% vs 11%; <italic>P</italic> &#x3d; .030) (<xref
                        ref-type="table" rid="T1">Table 1</xref>). Median follow-up was 8.5 years,
                    and 5-year FFS rates were 55% vs 70% for patients with high vs low FOXP1
                    expression, respectively (<xref ref-type="fig" rid="F2">Figure 2A</xref>). The
                    overall survival (OS) rate was lower in patients with high FOXP1 expression (72%
                    vs 83%), but this difference was not statistically significant (<italic>P</italic>
                    &#x3d; .13) (<xref ref-type="fig" rid="F2">Figure 2B</xref>).</p>
                <table-wrap id="T1" position="float">
                    <label>Table 1.</label>
                    <caption>
                        <p id="sec-p-015">Patient characteristics by FOXP1 expression status</p>
                    </caption>
                    <table frame="hsides">
                        <thead valign="bottom">
                            <tr>
                                <th rowspan="2" />
                                <th colspan="4" align="center">BCCA</th>
                                <th colspan="4" align="center">GLSG</th>
                            </tr>
                            <tr>
                                <th align="center">Evaluable</th>
                                <th align="center">FOXP1 low, n (%)</th>
                                <th align="center">FOXP1 high, n (%)</th>
                                <th align="center">
                                    <italic>P</italic>
                                </th>
                                <th align="center">Evaluable</th>
                                <th align="center">FOXP1 low, n (%)</th>
                                <th align="center">FOXP1 high, n (%)</th>
                                <th align="center">
                                    <italic>P</italic>
                                </th>
                            </tr>
                        </thead>
                        <tbody valign="top">
                            <tr>
                                <td>Age &#x2264;60 years</td>
                                <td rowspan="2" align="char" char=".">142</td>
                                <td align="char" char="(">29 (44%)</td>
                                <td align="char" char="(">41 (54%)</td>
                                <td />
                                <td rowspan="2" align="char" char=".">395</td>
                                <td align="char" char="(">45 (31%)</td>
                                <td align="char" char="(">67 (27%)</td>
                                <td />
                            </tr>
                            <tr>
                                <td>Age &#x3e;60 years</td>
                                <td align="char" char="(">37 (56%)</td>
                                <td align="char" char="(">35 (46%)</td>
                                <td align="char" char=".">.245</td>
                                <td align="char" char="(">102 (69%)</td>
                                <td align="char" char="(">181 (73%)</td>
                                <td align="char" char=".">.42</td>
                            </tr>
                            <tr>
                                <td>ECOG &#x2264;1</td>
                                <td rowspan="2" align="char" char=".">140</td>
                                <td align="char" char="(">54 (83%)</td>
                                <td align="char" char="(">68 (91%)</td>
                                <td />
                                <td rowspan="2" align="char" char=".">389</td>
                                <td align="char" char="(">138 (95%)</td>
                                <td align="char" char="(">225 (93%)</td>
                                <td />
                            </tr>
                            <tr>
                                <td>ECOG &#x3e;1</td>
                                <td align="char" char="(">11 (17%)</td>
                                <td align="char" char="(">7 (9%)</td>
                                <td align="char" char=".">.100</td>
                                <td align="char" char="(">8 (5%)</td>
                                <td align="char" char="(">18 (7%)</td>
                                <td align="char" char=".">.60</td>
                            </tr>
                            <tr>
                                <td>Stage I</td>
                                <td rowspan="4" align="char" char=".">142</td>
                                <td align="char" char="(">1 (2%)</td>
                                <td align="char" char="(">1 (1%)</td>
                                <td rowspan="4" align="char" char=".">.837</td>
                                <td rowspan="4" align="char" char=".">393</td>
                                <td align="center">&#x2014;</td>
                                <td align="center">&#x2014;</td>
                                <td rowspan="4" align="char" char=".">
                                    <bold>&#x3c;.001</bold>
                                </td>
                            </tr>
                            <tr>
                                <td>Stage II</td>
                                <td align="char" char="(">6 (9%)</td>
                                <td align="char" char="(">6 (8%)</td>
                                <td align="center">&#x2014;</td>
                                <td align="center">&#x2014;</td>
                            </tr>
                            <tr>
                                <td>Stage III</td>
                                <td align="char" char="(">25 (38%)</td>
                                <td align="char" char="(">24 (32%)</td>
                                <td align="char" char="(">66 (45%)</td>
                                <td align="char" char="(">68 (28%)</td>
                            </tr>
                            <tr>
                                <td>Stage IV</td>
                                <td align="char" char="(">34 (52%)</td>
                                <td align="char" char="(">45 (59%)</td>
                                <td align="char" char="(">81 (65%)</td>
                                <td align="char" char="(">178 (72%)</td>
                            </tr>
                            <tr>
                                <td>No. of nodal sites &#x2264;4</td>
                                <td rowspan="2" align="char" char=".">140</td>
                                <td align="char" char="(">18 (28%)</td>
                                <td align="char" char="(">16 (21%)</td>
                                <td />
                                <td rowspan="2" align="char" char=".">380</td>
                                <td align="char" char="(">57 (40%)</td>
                                <td align="char" char="(">54 (23%)</td>
                                <td />
                            </tr>
                            <tr>
                                <td>No. of nodal sites &#x3e;4</td>
                                <td align="char" char="(">47 (72%)</td>
                                <td align="char" char="(">59 (79%)</td>
                                <td align="char" char=".">.432</td>
                                <td align="char" char="(">87 (60%)</td>
                                <td align="char" char="(">182 (77%)</td>
                                <td align="char" char=".">
                                    <bold>&#x3c;.001</bold>
                                </td>
                            </tr>
                            <tr>
                                <td>LDH normal</td>
                                <td rowspan="2" align="char" char=".">135</td>
                                <td align="char" char="(">55 (89%)</td>
                                <td align="char" char="(">53 (73%)</td>
                                <td />
                                <td rowspan="2" align="char" char=".">387</td>
                                <td align="char" char="(">112 (78%)</td>
                                <td align="char" char="(">161 (66%)</td>
                                <td />
                            </tr>
                            <tr>
                                <td>LDH elevated</td>
                                <td align="char" char="(">7 (11%)</td>
                                <td align="char" char="(">20 (27%)</td>
                                <td align="char" char=".">
                                    <bold>.030</bold>
                                </td>
                                <td align="char" char="(">32 (22%)</td>
                                <td align="char" char="(">82 (34%)</td>
                                <td align="char" char=".">
                                    <bold>.022</bold>
                                </td>
                            </tr>
                            <tr>
                                <td>Hemoglobin &#x2265;120 g/L</td>
                                <td rowspan="2" align="char" char=".">138</td>
                                <td align="char" char="(">6 (9%)</td>
                                <td align="char" char="(">10 (14%)</td>
                                <td />
                                <td rowspan="2" align="char" char=".">387</td>
                                <td align="char" char="(">125 (86%)</td>
                                <td align="char" char="(">181 (72%)</td>
                                <td />
                            </tr>
                            <tr>
                                <td>Hemoglobin &#x3c;120 g/L</td>
                                <td align="char" char="(">58 (81%)</td>
                                <td align="char" char="(">64 (86%)</td>
                                <td align="char" char=".">.596</td>
                                <td align="char" char="(">21 (14%)</td>
                                <td align="char" char="(">70 (28%)</td>
                                <td align="char" char=".">
                                    <bold>.020</bold>
                                </td>
                            </tr>
                            <tr>
                                <td>FLIPI low/intermediate</td>
                                <td rowspan="2" align="char" char=".">138</td>
                                <td align="char" char="(">32 (49%)</td>
                                <td align="char" char="(">36 (49%)</td>
                                <td />
                                <td rowspan="2" align="char" char=".">383</td>
                                <td align="char" char="(">96 (67%)</td>
                                <td align="char" char="(">110 (46%)</td>
                                <td />
                            </tr>
                            <tr>
                                <td>
                                    <bold>FLIPI high</bold>
                                </td>
                                <td align="char" char="(">33 (51%)</td>
                                <td align="char" char="(">37 (51%)</td>
                                <td align="char" char=".">1.000</td>
                                <td align="char" char="(">47 (33%)</td>
                                <td align="char" char="(">130 (54%)</td>
                                <td align="char" char=".">
                                    <bold>&#x3c;.001</bold>
                                </td>
                            </tr>
                            <tr>
                                <td>m7-FLIPI low</td>
                                <td rowspan="2" align="char" char=".">107</td>
                                <td align="char" char="(">44 (85%)</td>
                                <td align="char" char="(">39 (71%)</td>
                                <td />
                                <td rowspan="2" align="char" char=".">87</td>
                                <td align="char" char="(">22 (81%)</td>
                                <td align="char" char="(">41 (68%)</td>
                                <td />
                            </tr>
                            <tr>
                                <td>m7-FLIPI high</td>
                                <td align="char" char="(">8 (15%)</td>
                                <td align="char" char="(">16 (29%)</td>
                                <td align="char" char=".">.108</td>
                                <td align="char" char="(">5 (19%)</td>
                                <td align="char" char="(">19 (32%)</td>
                                <td align="char" char=".">.312</td>
                            </tr>
                            <tr>
                                <td><italic>R</italic>-chemotherapy<bold>&#x2a;</bold></td>
                                <td rowspan="2" align="char" char=".">142</td>
                                <td align="char" char="(">66 (100%)</td>
                                <td align="char" char="(">76 (100%)</td>
                                <td />
                                <td rowspan="2" align="char" char=".">395</td>
                                <td align="char" char="(">72 (49%)</td>
                                <td align="char" char="(">132 (53%)</td>
                                <td />
                            </tr>
                            <tr>
                                <td>Chemotherapy<bold>&#x2a;</bold></td>
                                <td align="center">&#x2014;</td>
                                <td align="center">&#x2014;</td>
                                <td align="center">N/A</td>
                                <td align="char" char="(">75 (51%)</td>
                                <td align="char" char="(">116 (47%)</td>
                                <td align="char" char=".">.48</td>
                            </tr>
                            <tr>
                                <td>R maintenance</td>
                                <td rowspan="2" align="char" char=".">142</td>
                                <td align="char" char="(">57 (86%)</td>
                                <td align="char" char="(">60 (79%)</td>
                                <td />
                                <td rowspan="2" align="char" char=".">395</td>
                                <td align="center">&#x2014;</td>
                                <td align="center">&#x2014;</td>
                                <td />
                            </tr>
                            <tr>
                                <td>No R maintenance</td>
                                <td align="char" char="(">9 (14%)</td>
                                <td align="char" char="(">16 (21%)</td>
                                <td align="char" char=".">.276</td>
                                <td align="char" char="(">147 (100%)</td>
                                <td align="char" char="(">248 (100%)</td>
                                <td align="center">N/A</td>
                            </tr>
                        </tbody>
                    </table>
                    <table-wrap id="table-001" -foot>
                        <fn fn-type="other">
                            <p id="sec-p-016">ECOG, Eastern Cooperative Oncology Group performance status; NA, not
                                applicable; R, rituximab.</p>
                        </fn>
                        <fn fn-type="other">
                            <p id="sec-p-017">&#x2a;Chemotherapy refers to CVP for BCCA patients and CHOP for GLSG
                                patients.</p>
                        </fn>
                    </table-wrap-foot>
                </table-wrap>
                <fig id="fig-F2" placement="[htbp]">
                    <label>Figure 2.</label>
                    <caption>
                        <p id="sec-p-018"><bold>FOXP1 protein expression levels identify a group of patients with
                            inferior survival.</bold> (A) In the training cohort, we applied
                            log-rank statistics to determine the cutoff value of percent
                            FOXP1-positive tumor cells at which the best separation between rates of
                            FFS in 2 groups could be achieved. The cutoff point was subsequently
                            locked at &#x3e;10% and transferred to the validation cohort. Five-year
                            FFS was 55% vs 70% in patients with high and low FOXP1 expression,
                            respectively. (B) OS by FOXP1 expression status in the training cohort.
                            Five-year OS was 72% vs 83% in patients with high and low FOXP1
                            expression, respectively. (C) FOXP1 protein expression was significantly
                            associated with FFS in the validation cohort in <italic>R</italic>-CHOP&#x2013;treated
                            patients. Five-year FFS for high vs low FOXP1 expression was 22% vs 32%
                            in CHOP-treated patients and 55% vs 72% in <italic>R</italic>-CHOP&#x2013;treated
                            patients. (D) No clear association between FOXP1 expression and OS was
                            found in the validation cohort.</p>
                    </caption>
                    <image src="../images/LSA-99999_fig3.tif" width="0.82\linewidth" />
                </fig>
            </sec>
            <sec id="sec-010">
                <title>Correlation of FOXP1 staining with outcome in the validation cohort</title>
                <p id="sec-p-019">We performed validation in an independent cohort of patients treated with <italic>
                    R</italic>-CHOP or CHOP without rituximab within prospective phase 3 trials
                    conducted by the GLSG. A total of 390 patients were evaluable for FFS (191 CHOP,
                    199 <italic>R</italic>-CHOP) and 395 patients (191 CHOP, 204 <italic>R</italic>-CHOP)
                    for OS. The validation cohort differed from the training cohort by several
                    clinical risk factors, but neither by FLIPI nor by m7-FLIPI (supplemental Table
                    2). In the validation cohort, 248 patients (63%) had high expression of FOXP1,
                    which was slightly higher than in the BCCA cohort (<italic>P</italic> &#x3d;
                    .058). Adverse clinical risk factors such as stage, number of nodal sites, LDH,
                    and low hemoglobin levels were enriched in patients with high FOXP1 expression
                    who, as a consequence, were more often categorized as having high-risk disease
                    by FLIPI (54% vs 34%; <italic>P</italic> &#x3c; .001) (<xref ref-type="table"
                        rid="T1">Table 1</xref>).</p>
                <p id="sec-p-020">Median follow-up was 7.8 years. The primary analysis with FFS and OS censored for
                    ASCT and adjusted for rituximab revealed a significant association of high FOXP1
                    expression with unfavorable FFS (HR, 1.37; 95% confidence interval [CI],
                    1.02-1.86; <italic>P</italic> &#x3d; .040), but not with OS (HR, 0.98; 95% CI,
                    0.63-1.53; <italic>P</italic> &#x3d; .93). However, the interaction analysis
                    revealed that high FOXP1 expression was associated with significantly shorter
                    FFS in patients treated with <italic>R</italic>-CHOP (HR, 1.95; 95% CI,
                    1.13-3.38; <italic>P</italic> &#x3d; .017), but not in patients treated with
                    CHOP (HR, 1.15; 95% CI, 0.80-1.67; <italic>P</italic> &#x3d; .44). Five-year FFS
                    rates for high vs low FOXP1 expression were 22% vs 32% in CHOP-treated patients
                    and 55% vs 72% in <italic>R</italic>-CHOP&#x2013;treated patients, respectively
                    (<xref ref-type="fig" rid="F2">Figure 2C</xref>). No significant association was
                    found for FOXP1 staining with OS, but we observed a potential effect of
                    shortened OS with high FOXP1 expression among <italic>R</italic>-CHOP&#x2013;treated
                    patients (<italic>R</italic>-CHOP: HR, 1.82; 95% CI, 0.83-4.01; <italic>P</italic>
                    &#x3d; .14; CHOP: HR, 0.68; 95% CI, 0.39-1.18; <italic>P</italic> &#x3d; .17),
                    which was similar to the result observed in the training cohort (<xref
                        ref-type="fig" rid="F2">Figure 2D</xref>). We performed a sensitivity
                    analysis in which those patients who underwent ASCT were not censored at the
                    time of stem cell reinfusion. This analysis showed similar results for FFS (<italic>
                    R</italic>-CHOP: HR, 1.81; 95% CI, 1.09-3.01; <italic>P</italic> &#x3d; .022;
                    CHOP: HR, 1.19; 95% CI, 0.84-1.68; <italic>P</italic> &#x3d; .34) and OS (<italic>
                    R</italic>-CHOP: HR, 1.43; 95% CI, 0.72-2.86; <italic>P</italic> &#x3d; .31;
                    CHOP: HR, 0.73; 95% CI, 0.43-1.23; <italic>P</italic> &#x3d; .23).</p>
            </sec>
            <sec id="sec-011">
                <title>Multivariate analyses</title>
                <p id="sec-p-021">In order to take potential confounding by clinical covariates into account, we
                    performed separate multivariate analyses in the 2 outcome cohorts (<xref
                        ref-type="table" rid="T2">Table 2</xref>). In BCCA patients, high FOXP1
                    expression remained significantly associated with inferior FFS in a multivariate
                    Cox regression model including rituximab maintenance (by intent to treat) and
                    FLIPI high vs low/intermediate (HR, 1.84; 95% CI, 1.10-3.08; <italic>P</italic>
                    &#x3d; .021). In a similar manner, in the GLSG cohort, high FOXP1 expression was
                    significantly associated with poor FFS in patients treated with <italic>R</italic>-CHOP,
                    after adjustment for rituximab, binary FLIPI, and the interaction of FOXP1 with
                    rituximab (HR, 1.84; 95% CI, 1.05-3.24; <italic>P</italic> &#x3d; .035). No
                    significant association was observed in patients treated with CHOP (HR, 1.06;
                    95% CI, 0.73-1.54; <italic>P</italic> &#x3d; .76). Adjustment for individual
                    FLIPI factors yielded qualitatively similar results in both the BCCA and GLSG
                    cohorts (supplemental Table 3).</p>
                <table-wrap id="T2" position="float">
                    <label>Table 2.</label>
                    <caption>
                        <p id="sec-p-022">Multivariate analyses</p>
                    </caption>
                    <table frame="hsides">
                        <thead valign="bottom">
                            <tr>
                                <th rowspan="2">Cohort</th>
                                <th rowspan="2" align="center" />
                                <th colspan="3" align="center">FFS</th>
                                <th colspan="3" align="center">OS</th>
                            </tr>
                            <tr>
                                <th align="center">HR</th>
                                <th align="center">95% CI</th>
                                <th align="center">
                                    <italic>P</italic>
                                </th>
                                <th align="center">HR</th>
                                <th align="center">95% CI</th>
                                <th align="center">
                                    <italic>P</italic>
                                </th>
                            </tr>
                        </thead>
                        <tbody valign="top">
                            <tr>
                                <td>BCCA<bold>&#x2a;</bold></td>
                                <td>FOXP1 high</td>
                                <td align="char" char=".">1.84</td>
                                <td align="char" char=".">1.10-3.08</td>
                                <td align="char" char=".">
                                    <bold>.021</bold>
                                </td>
                                <td align="char" char=".">2.04</td>
                                <td align="char" char=".">1.08-3.86</td>
                                <td align="char" char=".">
                                    <bold>.029</bold>
                                </td>
                            </tr>
                            <tr>
                                <td />
                                <td>R maintenance</td>
                                <td align="char" char=".">0.89</td>
                                <td align="char" char=".">0.49-1.61</td>
                                <td align="char" char=".">.700</td>
                                <td align="char" char=".">1.53</td>
                                <td align="char" char=".">0.69-3.38</td>
                                <td align="char" char=".">.292</td>
                            </tr>
                            <tr>
                                <td />
                                <td>FLIPI high risk</td>
                                <td align="char" char=".">2.19</td>
                                <td align="char" char=".">1.31-3.66</td>
                                <td align="char" char=".">
                                    <bold>.003</bold>
                                </td>
                                <td align="char" char=".">4.23</td>
                                <td align="char" char=".">2.07-8.61</td>
                                <td align="char" char=".">
                                    <bold>&#x3c;.001</bold>
                                </td>
                            </tr>
                            <tr>
                                <td>GLSG model without FLIPI<bold>&#x2020;</bold></td>
                                <td>FOXP1 high (no R)</td>
                                <td align="char" char=".">1.15</td>
                                <td align="char" char=".">0.80-1.67</td>
                                <td align="char" char=".">.44</td>
                                <td align="char" char=".">0.68</td>
                                <td align="char" char=".">0.39-1.18</td>
                                <td align="char" char=".">.17</td>
                            </tr>
                            <tr>
                                <td />
                                <td>FOXP1 high (R)</td>
                                <td align="char" char=".">1.95</td>
                                <td align="char" char=".">1.13-3.38</td>
                                <td align="char" char=".">
                                    <bold>.017</bold>
                                </td>
                                <td align="char" char=".">1.82</td>
                                <td align="char" char=".">0.83-4.01</td>
                                <td align="char" char=".">.14</td>
                            </tr>
                            <tr>
                                <td />
                                <td>First-line rituximab (FOXP1 low)</td>
                                <td align="char" char=".">0.25</td>
                                <td align="char" char=".">0.14-0.44</td>
                                <td align="char" char=".">
                                    <bold>&#x3c;.001</bold>
                                </td>
                                <td align="char" char=".">0.37</td>
                                <td align="char" char=".">0.16-0.83</td>
                                <td align="char" char=".">
                                    <bold>.016</bold>
                                </td>
                            </tr>
                            <tr>
                                <td />
                                <td>First-line rituximab (FOXP1 high)</td>
                                <td align="char" char=".">0.42</td>
                                <td align="char" char=".">0.30-0.60</td>
                                <td align="char" char=".">
                                    <bold>&#x3c;.001</bold>
                                </td>
                                <td align="char" char=".">0.99</td>
                                <td align="char" char=".">0.58-1.67</td>
                                <td align="char" char=".">.96</td>
                            </tr>
                            <tr>
                                <td />
                                <td>FOXP1:rituximab (interaction term)</td>
                                <td align="char" char=".">1.69</td>
                                <td align="char" char=".">0.98-3.27</td>
                                <td align="char" char=".">.12</td>
                                <td align="char" char=".">2.68</td>
                                <td align="char" char=".">1.02-7.02</td>
                                <td align="char" char=".">
                                    <bold>.045</bold>
                                </td>
                            </tr>
                            <tr>
                                <td>GLSG model with FLIPI<bold>&#x2021;</bold></td>
                                <td>FOXP1 high (no R)</td>
                                <td align="char" char=".">1.06</td>
                                <td align="char" char=".">0.73-1.54</td>
                                <td align="char" char=".">.76</td>
                                <td align="char" char=".">0.62</td>
                                <td align="char" char=".">0.36-1.08</td>
                                <td align="char" char=".">.092</td>
                            </tr>
                            <tr>
                                <td />
                                <td>FOXP1 high (R)</td>
                                <td align="char" char=".">1.84</td>
                                <td align="char" char=".">1.05-3.24</td>
                                <td align="char" char=".">
                                    <bold>.035</bold>
                                </td>
                                <td align="char" char=".">1.38</td>
                                <td align="char" char=".">0.62-3.08</td>
                                <td align="char" char=".">.43</td>
                            </tr>
                            <tr>
                                <td />
                                <td>First-line rituximab (FOXP1 low)</td>
                                <td align="char" char=".">0.23</td>
                                <td align="char" char=".">0.13-0.42</td>
                                <td align="char" char=".">
                                    <bold>&#x3c;.001</bold>
                                </td>
                                <td align="char" char=".">0.38</td>
                                <td align="char" char=".">0.17-0.86</td>
                                <td align="char" char=".">
                                    <bold>.019</bold>
                                </td>
                            </tr>
                            <tr>
                                <td />
                                <td>First-line rituximab (FOXP1 high)</td>
                                <td align="char" char=".">0.41</td>
                                <td align="char" char=".">0.28-0.58</td>
                                <td align="char" char=".">
                                    <bold>&#x3c;.001</bold>
                                </td>
                                <td align="char" char=".">0.85</td>
                                <td align="char" char=".">0.49-1.46</td>
                                <td align="char" char=".">.55</td>
                            </tr>
                            <tr>
                                <td />
                                <td>FOXP1:rituximab (interaction term)</td>
                                <td align="char" char=".">1.74</td>
                                <td align="char" char=".">0.89-3.40</td>
                                <td align="char" char=".">.11</td>
                                <td align="char" char=".">2.23</td>
                                <td align="char" char=".">0.85-5.90</td>
                                <td align="char" char=".">.10</td>
                            </tr>
                            <tr>
                                <td />
                                <td>FLIPI high risk</td>
                                <td align="char" char=".">1.62</td>
                                <td align="char" char=".">1.21-2.17</td>
                                <td align="char" char=".">
                                    <bold>.0014</bold>
                                </td>
                                <td align="char" char=".">2.78</td>
                                <td align="char" char=".">1.74-4.43</td>
                                <td align="char" char=".">
                                    <bold>&#x3c;.001</bold>
                                </td>
                            </tr>
                        </tbody>
                    </table>
                    <table-wrap id="table-002" -foot>
                        <fn fn-type="other">
                            <p id="sec-p-023">R, rituximab.</p>
                        </fn>
                        <fn fn-type="other">
                            <p id="sec-p-024">&#x2a;n &#x3d; 138 patients/64 events for FFS, 43 events for OS.</p>
                        </fn>
                        <fn fn-type="other">
                            <p id="sec-p-025">&#x2020;n &#x3d; 390 patients/191 events for FFS, n &#x3d; 395
                                patients/86 events for OS.</p>
                        </fn>
                        <fn fn-type="other">
                            <p id="sec-p-026">&#x2021;n &#x3d; 381 patients/189 events for FFS, n &#x3d; 383
                                patients/84 events for OS.</p>
                        </fn>
                    </table-wrap-foot>
                </table-wrap>
                <p id="sec-p-027">In an exploratory analysis, we assessed the relationship of FOXP1 IHC with the
                    m7-FLIPI clinicogenetic risk model. High FOXP1 expression was more common in
                    m7-FLIPI high-risk patients, but this association did not reach statistical
                    significance (<xref ref-type="table" rid="T1">Table 1</xref>). To determine
                    whether FOXP1 expression adds prognostic information independently of the
                    m7-FLIPI, we performed multivariate analyses. Both variables were available for
                    107 patients from the BCCA cohort and 87 patients from the GLSG cohort. In these
                    subgroups, the HR for FFS with high FOXP1 expression, when adjusted for binary
                    m7-FLIPI status, was 1.74 in both cohorts (BCCA: 95% CI, 0.98-3.08; <italic>P</italic>
                    &#x3d; .059; GLSG: 95% CI, 0.79-3.11; <italic>P</italic> &#x3d; .203).</p>
            </sec>
            <sec id="sec-012">
                <title>Molecular characteristics by FOXP1 expression</title>
                <p id="sec-p-028">The correlation of high FOXP1 expression with unfavorable FFS in <italic>R</italic>-chemotherapy&#x2013;treated
                    patients prompted us to assess whether FOXP1 expression is a phenotypic marker
                    underlying distinct biological FL subsets. First, we determined in a pairwise
                    fashion whether recurrent gene mutations, in addition to <italic>EZH2</italic>
                    and <italic>MEF2B</italic>, are enriched in FOXP1 high or low expressors.
                    Considering only genes that were mutated in &#x3e;5% of patients in the data
                    sets of either Pastore et al.<sup>
                        <xref ref-type="bibr" rid="B20">20</xref>
                    </sup> or
                    Kridel et al.<sup>
                        <xref ref-type="bibr" rid="B11">11</xref>
                    </sup> (n
                    &#x3d; 22 genes; n &#x3d; 324 FL samples) and adjusting for false discovery
                    rate, we found 3 additional gene mutations to be significantly associated with
                    FOXP1 expression: <italic>GNA13</italic> and <italic>TNFRSF14</italic> mutations
                    were enriched in cases with low FOXP1 expression (odds ratio [OR], 0.18 and
                    0.46, respectively), whereas <italic>TP53</italic> mutations were more commonly
                    observed in cases with high FOXP1 expression (OR, 2.94) (<xref ref-type="fig"
                        rid="F3">Figure 3A</xref>). Several pathological characteristics were
                    unevenly distributed across the FOXP1 expression spectrum, with high FOXP1
                    expression significantly associated with the absence of <italic>BCL2</italic>
                    translocations and the presence of IRF4 protein expression. The association
                    between FOXP1 and IRF4 expression was validated, whereas the association between
                    FOXP1 expression and <italic>BCL2</italic> translocation status did not reach
                    statistical significance in GLSG patients (<xref ref-type="table" rid="T3">Table
                    3</xref>). A previous study reported that distinct subtypes exist in FL, one
                    resembling normal centrocytes, and another one more closely related to in
                    vitro&#x2013;activated B cells.<sup>
                        <xref ref-type="bibr" rid="B42">42</xref>
                    </sup> This
                    finding led us to explore whether signatures indicative of discrete GC and
                    post-GCB stages were associated with FOXP1 expression. GSEA showed that an ABC
                    signature and a signature derived from normal GC dark zone cells were
                    significantly enriched in cases with high FOXP1 expression (<xref ref-type="fig"
                        rid="F3">Figure 3B</xref>). Conversely, a GCB signature and genes related to
                    normal GC light zone cells were significantly enriched in patients with low
                    FOXP1 expression (<xref ref-type="fig" rid="F3">Figure 3C</xref>). A broader
                    analysis of gene expression changes in FOXP1 high vs low expressors showed
                    enrichment of multiple gene sets related to cell cycle in FOXP1 high expressors
                    (supplemental Table 2). Taken together, these observations suggest that FOXP1
                    expression delineates FL cases with distinct genomic and phenotypic
                    characteristics.</p>
                <fig id="fig-F3" placement="[htbp]">
                    <label>Figure 3.</label>
                    <caption>
                        <p id="sec-p-029"><bold>FOXP1 expression identifies FL with distinct molecular features.</bold>
                            (A) Volcano plot displaying gene mutations associated with FOXP1
                            expression. Only genes that were mutated in &#x3e;5% of patients in the
                            data sets of either Pastore et al<sup>
                                <xref ref-type="bibr" rid="B20">20</xref>
                            </sup>
                            or Kridel et al<sup>
                                <xref ref-type="bibr" rid="B11">11</xref>
                            </sup>
                            (n &#x3d; 22 genes; n &#x3d; 324 FL samples) were considered. After
                            adjustment for false discovery, 5 gene mutations were found to be
                            significantly associated with FOXP1 expression. <italic>GNA13</italic>, <italic>
                            EZH2</italic>, <italic>TNFRSF14,</italic> and <italic>MEF2B</italic>
                            mutations were enriched in cases with low FOXP1 expression (ORs: 0.18,
                            0.39, 0.46, and 0.38, respectively), whereas <italic>TP53</italic>
                            mutations were more commonly observed in cases with high FOXP1
                            expression (OR, 2.94). (B) GSEA shows that an activated B-cell signature
                            and a signature derived from normal GC dark zone cells were
                            significantly enriched in cases with high FOXP1 expression. (C)
                            Conversely, a GCB signature and genes related to normal GC light zone
                            cells were significantly enriched in cases with low FOXP1 expression.
                            ES, enrichment score.</p>
                    </caption>
                    <image src="../images/LSA-99999_fig6.tif" width="0.82\linewidth" />
                </fig>
                <table-wrap id="T3" position="float">
                    <label>Table 3.</label>
                    <caption>
                        <p id="sec-p-030">Pathological characteristics in FOXP1 negative and positive FL cases</p>
                    </caption>
                    <table frame="hsides">
                        <thead valign="bottom">
                            <tr>
                                <th />
                                <th colspan="4" align="center">BCCA</th>
                                <th colspan="4" align="center">GLSG</th>
                            </tr>
                            <tr>
                                <th />
                                <th align="center">Evaluable</th>
                                <th align="center">FOXP1 low, n (%)</th>
                                <th align="center">FOXP1 high, n (%)</th>
                                <th align="center">
                                    <italic>P</italic>
                                </th>
                                <th align="center">Evaluable</th>
                                <th align="center">FOXP1 low, n (%)</th>
                                <th align="center">FOXP1 high, n (%)</th>
                                <th align="center">
                                    <italic>P</italic>
                                </th>
                            </tr>
                        </thead>
                        <tbody valign="top">
                            <tr>
                                <td>Grade 1-2</td>
                                <td rowspan="2" align="char" char=".">252</td>
                                <td align="char" char="(">91 (85%)</td>
                                <td align="char" char="(">126 (87%)</td>
                                <td />
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                            </tr>
                            <tr>
                                <td>Grade 3A</td>
                                <td align="char" char="(">16 (15%)</td>
                                <td align="char" char="(">19 (12%)</td>
                                <td align="char" char=".">.715</td>
                            </tr>
                            <tr>
                                <td><italic>BCL2</italic> translocation negative</td>
                                <td rowspan="2" align="char" char=".">221</td>
                                <td align="char" char="(">7 (8%)</td>
                                <td align="char" char="(">26 (20%)</td>
                                <td />
                                <td rowspan="2" align="char" char=".">322</td>
                                <td align="char" char="(">14 (11%)</td>
                                <td align="char" char="(">37 (18%)</td>
                                <td />
                            </tr>
                            <tr>
                                <td><italic>BCL2</italic> translocation positive</td>
                                <td align="char" char="(">86 (92%)</td>
                                <td align="char" char="(">102 (80%)</td>
                                <td align="char" char=".">
                                    <bold>.012</bold>
                                </td>
                                <td align="char" char="(">106 (89%)</td>
                                <td align="char" char="(">165 (82%)</td>
                                <td align="char" char=".">.155</td>
                            </tr>
                            <tr>
                                <td><italic>BCL6</italic> translocation negative</td>
                                <td rowspan="2" align="char" char=".">232</td>
                                <td align="char" char="(">84 (88%)</td>
                                <td align="char" char="(">110 (81%)</td>
                                <td />
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                            </tr>
                            <tr>
                                <td><italic>BCL6</italic> translocation positive</td>
                                <td align="char" char="(">12 (13%)</td>
                                <td align="char" char="(">26 (19%)</td>
                                <td align="char" char=".">.210</td>
                            </tr>
                            <tr>
                                <td><italic>MYC</italic> translocation negative</td>
                                <td rowspan="2" align="char" char=".">197</td>
                                <td align="char" char="(">77 (96%)</td>
                                <td align="char" char="(">108 (92%)</td>
                                <td />
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                            </tr>
                            <tr>
                                <td><italic>MYC</italic> translocation positive</td>
                                <td align="char" char="(">3 (4%)</td>
                                <td align="char" char="(">9 (8%)</td>
                                <td align="char" char=".">.366</td>
                            </tr>
                            <tr>
                                <td>CD10 IHC negative</td>
                                <td rowspan="2" align="char" char=".">223</td>
                                <td align="char" char="(">7 (7%)</td>
                                <td align="char" char="(">11 (8%)</td>
                                <td />
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                            </tr>
                            <tr>
                                <td>CD10 IHC positive</td>
                                <td align="char" char="(">99 (93%)</td>
                                <td align="char" char="(">134 (92%)</td>
                                <td align="char" char=".">.810</td>
                            </tr>
                            <tr>
                                <td>BCL6 IHC negative</td>
                                <td rowspan="2" align="char" char=".">252</td>
                                <td align="char" char="(">4 (4%)</td>
                                <td align="char" char="(">5 (3%)</td>
                                <td />
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                            </tr>
                            <tr>
                                <td>BCL6 IHC positive</td>
                                <td align="char" char="(">103 (96%)</td>
                                <td align="char" char="(">140 (97%)</td>
                                <td align="char" char=".">1.000</td>
                            </tr>
                            <tr>
                                <td>IRF4 IHC negative</td>
                                <td rowspan="2" align="char" char=".">252</td>
                                <td align="char" char="(">106 (98%)</td>
                                <td align="char" char="(">127 (88%)</td>
                                <td />
                                <td rowspan="2" align="center">359</td>
                                <td align="char" char="(">123 (91%)</td>
                                <td align="char" char="(">174 (78%)</td>
                                <td />
                            </tr>
                            <tr>
                                <td>IRF4 IHC positive</td>
                                <td align="char" char="(">1 (2%)</td>
                                <td align="char" char="(">18 (12%)</td>
                                <td align="char" char=".">
                                    <bold>.002</bold>
                                </td>
                                <td align="char" char="(">12 (9%)</td>
                                <td align="char" char="(">50 (22%)</td>
                                <td align="char" char=".">
                                    <bold>.001</bold>
                                </td>
                            </tr>
                            <tr>
                                <td>TP53 IHC negative</td>
                                <td rowspan="2" align="char" char=".">252</td>
                                <td align="char" char="(">106 (99%)</td>
                                <td align="char" char="(">139 (96%)</td>
                                <td />
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                                <td rowspan="2" align="center">&#x2014;</td>
                            </tr>
                            <tr>
                                <td>TP53 IHC positive</td>
                                <td align="char" char="(">1 (1%)</td>
                                <td align="char" char="(">6 (4%)</td>
                                <td align="char" char=".">.244</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
            </sec>
        </sec>
        <sec id="sec-013" sec-type="discussion">
            <title>Discussion</title>
            <p id="sec-p-031">Although the clinicogenetic risk stratifier m7-FLIPI was shown to be a promising
                approach to delineate patient populations at differential risk of treatment failure,
                the mechanism underlying the association between mutation of the 7 genes included in
                the m7-FLIPI and outcome has, thus far, not been elucidated.<sup>
                    <xref ref-type="bibr" rid="B20">20</xref>
                </sup> Moreover,
                determination of m7-FLIPI status relies on mutational analysis, which may not be
                routinely available to most clinicians. Herein, we extended the prognostic value of
                individual gene mutations to FOXP1 protein expression, a downstream phenotypic
                surrogate marker of <italic>EZH2</italic> and/or <italic>MEF2B</italic> wild-type
                status. FOXP1 is a forkhead transcription factor that regulates normal B-cell
                development and is expressed in mantle zone rather than GC B cells.<sup><xref
                        ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref></sup>
                FOXP1 is also overexpressed in a subset of B-cell lymphomas, including the ABC
                subtype of DLBCL, and in lymphomas originating from mucosa-associated lymphoid
                tissue.<sup><xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr"
                        rid="B46">46</xref></sup> Whereas FOXP1 correlates with inferior survival in
                DLBCL in most studies, possibly due to its association with the ABC subtype,<sup><xref
                        ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B47">47</xref>
                ,<xref ref-type="bibr" rid="B48">48</xref></sup> its prognostic and correlative
                implications had not been comprehensively explored in FL.</p>
            <p id="sec-p-032">In the present study, we showed that FOXP1 expression is surprisingly common in FL,
                in keeping with a small series of 13 FL cases reported by Brown et al.<sup>
                    <xref ref-type="bibr" rid="B49">49</xref>
                </sup> We report that
                high FOXP1 expression was associated with adverse FFS in 2 independent FL cohorts
                treated with upfront immunochemotherapy: a population-based series of patients
                treated with <italic>R</italic>-CVP (and rituximab maintenance in 82% of patients)
                from the BCCA and a GLSG clinical trial cohort treated with <italic>R</italic>-CHOP,
                but without rituximab maintenance. Outcomes of patients with high and low expression
                of FOXP1 were similar between the BCCA cohort and the GLSG <italic>R</italic>-CHOP&#x2013;treated
                patients, despite differences in clinical characteristics and treatment between
                these 2 cohorts. On the other hand, FOXP1 did not separate distinct outcome groups
                in patients treated without rituximab, which suggests that FOXP1 is a predictive
                biomarker for outcome with immunochemotherapy.<sup>
                    <xref ref-type="bibr" rid="B50">50</xref>
                </sup> We documented
                that assessment of FOXP1 expression adds prognostic information in
                immunochemotherapy-treated patients, beyond well-established clinical risk factors.
                Indeed, in multivariate analyses, high FOXP1 expression remained significantly
                associated with FFS in such patients after adjustment for the FLIPI. OS was not
                significantly associated with FOXP1 expression, which may be explained by the effect
                of subsequent therapies after initial immunochemotherapy, or by insufficient
                statistical power to detect an OS effect. Although challenges with reproducibility
                of IHC are certainly recognized,<sup><xref ref-type="bibr" rid="B51">51</xref>,<xref
                        ref-type="bibr" rid="B52">52</xref></sup> it has advantages compared with
                genetic testing, being an indispensable part of the standard diagnostic lymphoma
                workup that can be performed at low cost and with rapid turnaround time. In
                addition, we show that IHC for FOXP1 serves as a phenotypic readout that integrates
                the effects from multiple upstream aberrations. However, our study was not
                sufficiently powered to determine whether FOXP1 expression adds prognostic
                information that is independent of the m7-FLIPI. This will have to be evaluated in
                larger data sets.</p>
            <p id="sec-p-033">Reported mechanisms of FOXP1 overexpression include <italic>IGH</italic> and non-<italic>
                IG</italic> rearrangements,<sup><xref ref-type="bibr" rid="B53">53</xref>,<xref
                        ref-type="bibr" rid="B54">54</xref></sup> trisomy of chromosome 3, and focal
                high-level amplifications.<sup>
                    <xref ref-type="bibr" rid="B41">41</xref>
                </sup> Conversely,
                microRNAs miR-34a and miR-150 have been reported to downregulate FOXP1 expression.<sup><xref
                        ref-type="bibr" rid="B55">55</xref><xref ref-type="bibr" rid="B56" />-<xref
                        ref-type="bibr" rid="B57">57</xref></sup> Our data demonstrate a novel,
                epigenetic mechanism of regulation of FOXP1 function, as <italic>EZH2</italic>
                mutations are robustly associated with decreased FOXP1 expression. In the B-cell
                lymphoma context, FOXP1 expression was shown to repress proapoptotic genes<sup>
                    <xref ref-type="bibr" rid="B58">58</xref>
                </sup>; promote Wnt
                signaling<sup>
                    <xref ref-type="bibr" rid="B59">59</xref>
                </sup>; suppress MHC
                class II expression<sup><xref ref-type="bibr" rid="B60">60</xref>,<xref
                        ref-type="bibr" rid="B61">61</xref></sup>; and modulate B-cell surface
                markers such as CD19,<sup><xref ref-type="bibr" rid="B60">60</xref>,<xref
                        ref-type="bibr" rid="B61">61</xref></sup> which potentially underlie
                treatment resistance and contribute to early progression. Dekker et al<sup>
                    <xref ref-type="bibr" rid="B61">61</xref>
                </sup> showed that
                FOXP1 represses the expression of genes defining the GCB identity, while favoring
                the expression of genes contributing to plasma cell differentiation. It is tempting
                to speculate that low FOXP1 expression is characteristic of a phenotype that is more
                sensitive to rituximab, potentially explaining the lack of prognostic effect in
                patients treated without rituximab. Future studies are warranted to explore whether
                FOXP1 expression might rationally guide the use of anti-CD20&#x2013;directed
                therapy, for example, with regard to the indication for maintenance therapy.</p>
            <p id="sec-p-034">Lastly, we leveraged available patient data sets to correlate FOXP1 protein
                expression with well-characterized genetic and phenotypic alterations. We found that
                cases with low FOXP1 expression were enriched for <italic>GNA13</italic> and <italic>
                TNFRSF14</italic> mutations, whereas high FOXP1 expressers were more frequently
                positive for IRF4 and more frequently had <italic>TP53</italic> mutation. Koues et
                al<sup>
                    <xref ref-type="bibr" rid="B42">42</xref>
                </sup> had previously
                identified distinct FL subtypes, with pathogenic regulatory circuitries resembling
                either centrocytes (subtype 1) or in vitro&#x2013;activated B cells (subtype 2).
                Using GSEA, we showed that GCB and light zone signatures were enriched in patients
                with low FOXP1 expression, whereas ABC and dark zone signatures were enriched in
                those with high FOXP1 expression. Phenotypes of FOXP1 high and low expression are
                thus reflective of distinct sets of molecular alterations. Moreover, our findings
                are hypothesis generating because they suggest that alternative treatment strategies
                should be explored in patients with high FOXP1 expression.</p>
            <p id="sec-p-035">Our results illustrate the value of understanding the intricate relationships between
                lymphoma biology and response to treatment, at once providing a predictive biomarker
                to guide patient management and highlighting discrete biological contrasts within
                the heterogeneous molecular landscape that is inherent to FL. Our study shows that
                FOXP1 is a marker of higher-risk FL in patients receiving <italic>R</italic>-CVP and <italic>
                R</italic>-CHOP, but additional independent studies in other cohorts are needed to
                document whether such an outcome correlation holds true with regimens that contain
                other anti-CD20 antibodies (eg, obinutuzumab) and/or chemotherapy backbone (ie,
                bendamustine).</p>
        </sec>
    </body>
    <back>
        <fn-group>
            <fn fn-type="supplementary-material">
                <p id="sec-p-036">The online version of this article contains a data supplement.</p>
            </fn>
            <fn fn-type="financial-disclosure">
                <p id="sec-p-037">The publication costs of this article were defrayed in part by page charge
                    payment. Therefore, and solely to indicate this fact, this article is hereby
                    marked &#x201c;advertisement&#x201d; in accordance with 18 USC section 1734.</p>
            </fn>
        </fn-group>
        <ack>
            <title>Acknowledgments</title>
            <p id="sec-p-038">This work was supported by a Program Project Grant from the Terry Fox Research
                Institute (<ext-link ext-link-type="uri" xlink:href="http://www.tfri.ca">
                http://www.tfri.ca</ext-link>, Grant No. 1023) (C.S., J.C., and R.D.G.), the
                Mildred-Scheel-Foundation for Cancer Research (Deutsche Krebshilfe), and the Michael
                Smith Foundation for Health Research and Lymphoma Canada (A.M.); the Max-Eder
                Program of the German Cancer Aid (110659) (O.W.); the German Research Foundation
                (DFG-SFB/CRC-1243, TP-A11); the Princess Margaret Cancer Centre; and the Leukemia
                &#x26; Lymphoma Society of Canada (R.K.).</p>
        </ack>
        <sec id="sec-014">
            <title>Authorship</title>
            <p id="sec-p-039">Contribution: A.M., V.J., E.H., O.W., and R.K. designed and performed the research,
                analyzed the data, and wrote the manuscript; P.F., E.L., and M.B. performed the
                research; and A.R., G.O., H.H., W.K., W.H., C.S., J.M.C., L.H.S., and R.D.G.
                collected and contributed samples and data.</p>
            <p id="sec-p-040">Conflict-of-interest disclosure: The authors declare no competing financial
                interests.</p>
            <p id="sec-p-041">Correspondence: Robert Kridel, Division of Medical Oncology and Hematology, Princess
                Margaret Cancer Centre, 610 University Ave, OPG 6<sup>th</sup> Floor, Suite 6-714,
                Toronto, ON M5G 2M9, Canada; e-mail: <email>suganya.srinivasan@tnqsoftware.co.in</email>
                .</p>
        </sec>
        <ref-list>
            <title>References</title>
            <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><collab>The Non-Hodgkin&#x2019;s Lymphoma
                    Classification Project</collab>. <article-title>A clinical evaluation of the
                    International Lymphoma Study Group classification of non-Hodgkin&#x2019;s
                    lymphoma</article-title>. <source>Blood</source>. <year>1997</year>;<volume>89</volume>
                    (<issue>11</issue>):<fpage>3909</fpage>-<lpage>3918</lpage>.</mixed-citation>
            </ref>
            <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Horning</surname>
                            <given-names>SJ</given-names>
                        </string-name>, <string-name>
                            <surname>Rosenberg</surname>
                            <given-names>SA</given-names>
                        </string-name></person-group>
                    . <article-title>The natural history of initially untreated low-grade
                    non-Hodgkin&#x2019;s lymphomas</article-title>. <source>N Engl J Med</source>. <year>
                    1984</year>;<volume>311</volume>(<issue>23</issue>):<fpage>1471</fpage>-<lpage>
                    1475</lpage>.</mixed-citation>
            </ref>
            <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Tsujimoto</surname>
                            <given-names>Y</given-names>
                        </string-name>, <string-name>
                            <surname>Finger</surname>
                            <given-names>LR</given-names>
                        </string-name>, <string-name>
                            <surname>Yunis</surname>
                            <given-names>J</given-names>
                        </string-name>, <string-name>
                            <surname>Nowell</surname>
                            <given-names>PC</given-names>
                        </string-name>, <string-name>
                            <surname>Croce</surname>
                            <given-names>CM</given-names>
                        </string-name></person-group>
                    . <article-title>Cloning of the chromosome breakpoint of neoplastic B cells with
                    the t(14;18) chromosome translocation</article-title>. <source>Science</source>. <year>
                    1984</year>;<volume>226</volume>(<issue>4678</issue>):<fpage>1097</fpage>-<lpage>
                    1099</lpage>.</mixed-citation>
            </ref>
            <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name>
                            <surname>Swerdlow</surname>
                            <given-names>SH</given-names>
                        </string-name>, <string-name>
                            <surname>Campo</surname>
                            <given-names>E</given-names>
                        </string-name>, <string-name>
                            <surname>Harris</surname>
                            <given-names>NL</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>WHO Classification of Tumours of Haematopoietic and Lymphoid
                    Tissues</article-title>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC
                    Lyon</publisher-name>; <year>2008</year></mixed-citation>
            </ref>
            <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Limpens</surname>
                            <given-names>J</given-names>
                        </string-name>, <string-name>
                            <surname>Stad</surname>
                            <given-names>R</given-names>
                        </string-name>, <string-name>
                            <surname>Vos</surname>
                            <given-names>C</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Lymphoma-associated translocation t(14;18) in blood B cells of
                    normal individuals</article-title>. <source>Blood</source>. <year>1995</year>;<volume>
                    85</volume>(<issue>9</issue>):<fpage>2528</fpage>-<lpage>2536</lpage>.</mixed-citation>
            </ref>
            <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Sch&#xfc;ler</surname>
                            <given-names>F</given-names>
                        </string-name>, <string-name>
                            <surname>D&#xf6;lken</surname>
                            <given-names>L</given-names>
                        </string-name>, <string-name>
                            <surname>Hirt</surname>
                            <given-names>C</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Prevalence and frequency of circulating t(14;18)-MBR
                    translocation carrying cells in healthy individuals</article-title>. <source>Int
                    J Cancer</source>. <year>2009</year>;<volume>124</volume>(<issue>4</issue>):<fpage>
                    958</fpage>-<lpage>963</lpage>.</mixed-citation>
            </ref>
            <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name>
                            <surname>Roulland</surname>
                            <given-names>S</given-names>
                        </string-name>, <string-name>
                            <surname>Faroudi</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Mamessier</surname>
                            <given-names>E</given-names>
                        </string-name>, <string-name>
                            <surname>Sungalee</surname>
                            <given-names>S</given-names>
                        </string-name>, <string-name>
                            <surname>Salles</surname>
                            <given-names>G</given-names>
                        </string-name>, <string-name>
                            <surname>Nadel</surname>
                            <given-names>B</given-names>
                        </string-name></person-group>
                    . <article-title>Early steps of follicular lymphoma pathogenesis.</article-title><source>Adv
                    Immunol</source>. <year>2011</year>;<volume>111</volume>:<fpage>1</fpage>-<lpage>
                    46</lpage>.</mixed-citation>
            </ref>
            <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Sungalee</surname>
                            <given-names>S</given-names>
                        </string-name>, <string-name>
                            <surname>Mamessier</surname>
                            <given-names>E</given-names>
                        </string-name>, <string-name>
                            <surname>Morgado</surname>
                            <given-names>E</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Germinal center reentries of BCL2-overexpressing B cells drive
                    follicular lymphoma progression</article-title>. <source>J Clin Invest</source>. <year>
                    2014</year>;<volume>124</volume>(<issue>12</issue>):<fpage>5337</fpage>-<lpage>
                    5351</lpage>.</mixed-citation>
            </ref>
            <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Pasqualucci</surname>
                            <given-names>L</given-names>
                        </string-name>, <string-name>
                            <surname>Khiabanian</surname>
                            <given-names>H</given-names>
                        </string-name>, <string-name>
                            <surname>Fangazio</surname>
                            <given-names>M</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Genetics of follicular lymphoma transformation</article-title>. <source>Cell
                    Reports</source>. <year>2014</year>;<volume>6</volume>(<issue>1</issue>):<fpage>
                    130</fpage>-<lpage>140</lpage>.</mixed-citation>
            </ref>
            <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Loeffler</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Kreuz</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Haake</surname>
                            <given-names>A</given-names>
                        </string-name>, <etal /></person-group>
                    ; <collab>HaematoSys-Project</collab>. <article-title>Genomic and epigenomic
                    co-evolution in follicular lymphomas</article-title>. <source>Leukemia</source>. <year>
                    2015</year>;<volume>29</volume>(<issue>2</issue>):<fpage>456</fpage>-<lpage>463</lpage>
                    .</mixed-citation>
            </ref>
            <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Kridel</surname>
                            <given-names>R</given-names>
                        </string-name>, <string-name>
                            <surname>Chan</surname>
                            <given-names>FC</given-names>
                        </string-name>, <string-name>
                            <surname>Mottok</surname>
                            <given-names>A</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Histological Transformation and Progression in Follicular
                    Lymphoma: A Clonal Evolution Study</article-title>. <source>PLoS Med</source>. <year>
                    2016</year>;<volume>13</volume>(<issue>12</issue>):<fpage>e1002197</fpage>.</mixed-citation>
            </ref>
            <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Green</surname>
                            <given-names>MR</given-names>
                        </string-name>, <string-name>
                            <surname>Gentles</surname>
                            <given-names>AJ</given-names>
                        </string-name>, <string-name>
                            <surname>Nair</surname>
                            <given-names>RV</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Hierarchy in somatic mutations arising during genomic evolution
                    and progression of follicular lymphoma</article-title>. <source>Blood</source>. <year>
                    2013</year>;<volume>121</volume>(<issue>9</issue>):<fpage>1604</fpage>-<lpage>
                    1611</lpage>.</mixed-citation>
            </ref>
            <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Okosun</surname>
                            <given-names>J</given-names>
                        </string-name>, <string-name>
                            <surname>B&#xf6;d&#xf6;r</surname>
                            <given-names>C</given-names>
                        </string-name>, <string-name>
                            <surname>Wang</surname>
                            <given-names>J</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Integrated genomic analysis identifies recurrent mutations and
                    evolution patterns driving the initiation and progression of follicular lymphoma</article-title>
                    . <source>Nat Genet</source>. <year>2014</year>;<volume>46</volume>(<issue>2</issue>
                    ):<fpage>176</fpage>-<lpage>181</lpage>.</mixed-citation>
            </ref>
            <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Green</surname>
                            <given-names>MR</given-names>
                        </string-name>, <string-name>
                            <surname>Kihira</surname>
                            <given-names>S</given-names>
                        </string-name>, <string-name>
                            <surname>Liu</surname>
                            <given-names>CL</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Mutations in early follicular lymphoma progenitors are
                    associated with suppressed antigen presentation</article-title>. <source>Proc
                    Natl Acad Sci USA</source>. <year>2015</year>;<volume>112</volume>(<issue>10</issue>
                    ):<fpage>E1116</fpage>-<lpage>E1125</lpage>.</mixed-citation>
            </ref>
            <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Morin</surname>
                            <given-names>RD</given-names>
                        </string-name>, <string-name>
                            <surname>Johnson</surname>
                            <given-names>NA</given-names>
                        </string-name>, <string-name>
                            <surname>Severson</surname>
                            <given-names>TM</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Somatic mutations altering EZH2 (Tyr641) in follicular and
                    diffuse large B-cell lymphomas of germinal-center origin</article-title>. <source>Nat
                    Genet</source>. <year>2010</year>;<volume>42</volume>(<issue>2</issue>):<fpage>
                    181</fpage>-<lpage>185</lpage>.</mixed-citation>
            </ref>
            <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Morin</surname>
                            <given-names>RD</given-names>
                        </string-name>, <string-name>
                            <surname>Mendez-Lago</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Mungall</surname>
                            <given-names>AJ</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Frequent mutation of histone-modifying genes in non-Hodgkin
                    lymphoma</article-title>. <source>Nature</source>. <year>2011</year>;<volume>476</volume>
                    (<issue>7360</issue>):<fpage>298</fpage>-<lpage>303</lpage>.</mixed-citation>
            </ref>
            <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Pasqualucci</surname>
                            <given-names>L</given-names>
                        </string-name>, <string-name>
                            <surname>Dominguez-Sola</surname>
                            <given-names>D</given-names>
                        </string-name>, <string-name>
                            <surname>Chiarenza</surname>
                            <given-names>A</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Inactivating mutations of acetyltransferase genes in B-cell
                    lymphoma</article-title>. <source>Nature</source>. <year>2011</year>;<volume>471</volume>
                    (<issue>7337</issue>):<fpage>189</fpage>-<lpage>195</lpage>.</mixed-citation>
            </ref>
            <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Solal-C&#xe9;ligny</surname>
                            <given-names>P</given-names>
                        </string-name>, <string-name>
                            <surname>Roy</surname>
                            <given-names>P</given-names>
                        </string-name>, <string-name>
                            <surname>Colombat</surname>
                            <given-names>P</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Follicular lymphoma international prognostic index</article-title>
                    . <source>Blood</source>. <year>2004</year>;<volume>104</volume>(<issue>5</issue>
                    ):<fpage>1258</fpage>-<lpage>1265</lpage>.</mixed-citation>
            </ref>
            <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Federico</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Bellei</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Marcheselli</surname>
                            <given-names>L</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Follicular lymphoma international prognostic index 2: a new
                    prognostic index for follicular lymphoma developed by the international
                    follicular lymphoma prognostic factor project</article-title>. <source>J Clin
                    Oncol</source>. <year>2009</year>;<volume>27</volume>(<issue>27</issue>):<fpage>
                    4555</fpage>-<lpage>4562</lpage>.</mixed-citation>
            </ref>
            <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Pastore</surname>
                            <given-names>A</given-names>
                        </string-name>, <string-name>
                            <surname>Jurinovic</surname>
                            <given-names>V</given-names>
                        </string-name>, <string-name>
                            <surname>Kridel</surname>
                            <given-names>R</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Integration of gene mutations in risk prognostication for
                    patients receiving first-line immunochemotherapy for follicular lymphoma: a
                    retrospective analysis of a prospective clinical trial and validation in a
                    population-based registry</article-title>. <source>Lancet Oncol</source>. <year>
                    2015</year>;<volume>16</volume>(<issue>9</issue>):<fpage>1111</fpage>-<lpage>
                    1122</lpage>.</mixed-citation>
            </ref>
            <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Huet</surname>
                            <given-names>S</given-names>
                        </string-name>, <string-name>
                            <surname>Xerri</surname>
                            <given-names>L</given-names>
                        </string-name>, <string-name>
                            <surname>Tesson</surname>
                            <given-names>B</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>EZH2 alterations in follicular lymphoma: biological and
                    clinical correlations</article-title>. <source>Blood Cancer J</source>. <year>
                    2017</year>;<volume>7</volume>(<issue>4</issue>):<fpage>e555</fpage>.</mixed-citation>
            </ref>
            <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name>
                            <surname>Stevens</surname>
                            <given-names>WBC</given-names>
                        </string-name>, <string-name>
                            <surname>Mendeville</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Redd</surname>
                            <given-names>R</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Prognostic relevance of CD163 and CD8 combined with EZH2 and
                    gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma
                    Biomarker Consortium</article-title>. <source>Haematologica</source>. <year>2017</year>
                    ;<volume>102</volume>(<issue>8</issue>):<fpage>1413</fpage>-<lpage>1423</lpage>.</mixed-citation>
            </ref>
            <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name>
                            <surname>Cao</surname>
                            <given-names>R</given-names>
                        </string-name>., <string-name>
                            <surname>Wang</surname>
                            <given-names>L</given-names>
                        </string-name>, <string-name>
                            <surname>Wang</surname>
                            <given-names>H</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Role of histone H3 lysine 27 methylation in Polycomb-group
                    silencing</article-title>. <source>Science</source>. <year>2002</year>;<volume>
                    298</volume>(<issue>5595</issue>):<fpage>1039</fpage>-<lpage>1043</lpage>.</mixed-citation>
            </ref>
            <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>M&#xfc;ller</surname>
                            <given-names>J</given-names>
                        </string-name>, <string-name>
                            <surname>Hart</surname>
                            <given-names>CM</given-names>
                        </string-name>, <string-name>
                            <surname>Francis</surname>
                            <given-names>NJ</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Histone methyltransferase activity of a Drosophila Polycomb
                    group repressor complex</article-title>. <source>Cell</source>. <year>2002</year>
                    ;<volume>111</volume>(<issue>2</issue>):<fpage>197</fpage>-<lpage>208</lpage>.</mixed-citation>
            </ref>
            <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Czermin</surname>
                            <given-names>B</given-names>
                        </string-name>, <string-name>
                            <surname>Melfi</surname>
                            <given-names>R</given-names>
                        </string-name>, <string-name>
                            <surname>McCabe</surname>
                            <given-names>D</given-names>
                        </string-name>, <string-name>
                            <surname>Seitz</surname>
                            <given-names>V</given-names>
                        </string-name>, <string-name>
                            <surname>Imhof</surname>
                            <given-names>A</given-names>
                        </string-name>, <string-name>
                            <surname>Pirrotta</surname>
                            <given-names>V</given-names>
                        </string-name></person-group>
                    . <article-title>Drosophila enhancer of Zeste/ESC complexes have a histone H3
                    methyltransferase activity that marks chromosomal Polycomb sites</article-title>
                    . <source>Cell</source>. <year>2002</year>;<volume>111</volume>(<issue>2</issue>
                    ):<fpage>185</fpage>-<lpage>196</lpage>.</mixed-citation>
            </ref>
            <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Vir&#xe9;</surname>
                            <given-names>E</given-names>
                        </string-name>, <string-name>
                            <surname>Brenner</surname>
                            <given-names>C</given-names>
                        </string-name>, <string-name>
                            <surname>Deplus</surname>
                            <given-names>R</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>The Polycomb group protein EZH2 directly controls DNA
                    methylation</article-title>. <source>Nature</source>. <year>2006</year>;<volume>
                    439</volume>(<issue>7078</issue>):<fpage>871</fpage>-<lpage>874</lpage>.</mixed-citation>
            </ref>
            <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>B&#xf6;d&#xf6;r</surname>
                            <given-names>C</given-names>
                        </string-name>, <string-name>
                            <surname>O&#x2019;Riain</surname>
                            <given-names>C</given-names>
                        </string-name>, <string-name>
                            <surname>Wrench</surname>
                            <given-names>D</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>EZH2 Y641 mutations in follicular lymphoma</article-title>. <source>
                    Leukemia</source>. <year>2011</year>;<volume>25</volume>(<issue>4</issue>):<fpage>
                    726</fpage>-<lpage>729</lpage>.</mixed-citation>
            </ref>
            <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>B&#xf6;d&#xf6;r</surname>
                            <given-names>C</given-names>
                        </string-name>, <string-name>
                            <surname>Grossmann</surname>
                            <given-names>V</given-names>
                        </string-name>, <string-name>
                            <surname>Popov</surname>
                            <given-names>N</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>EZH2 mutations are frequent and represent an early event in
                    follicular lymphoma</article-title>. <source>Blood</source>. <year>2013</year>;<volume>
                    122</volume>(<issue>18</issue>):<fpage>3165</fpage>-<lpage>3168</lpage>.</mixed-citation>
            </ref>
            <ref id="B29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Guo</surname>
                            <given-names>S</given-names>
                        </string-name>, <string-name>
                            <surname>Chan</surname>
                            <given-names>JKC</given-names>
                        </string-name>, <string-name>
                            <surname>Iqbal</surname>
                            <given-names>J</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>EZH2 mutations in follicular lymphoma from different ethnic
                    groups and associated gene expression alterations</article-title>. <source>Clin
                    Cancer Res</source>. <year>2014</year>;<volume>20</volume>(<issue>12</issue>):<fpage>
                    3078</fpage>-<lpage>3086</lpage>.</mixed-citation>
            </ref>
            <ref id="B30">
                <label>30.</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name>
                            <surname>Potthoff</surname>
                            <given-names>MJ</given-names>
                        </string-name>, <string-name>
                            <surname>Olson</surname>
                            <given-names>EN</given-names>
                        </string-name></person-group>
                    . <article-title>MEF2: a central regulator of diverse developmental programs</article-title>
                    . <source>Development</source>. <year>2007</year>;<volume>134</volume>(<issue>23</issue>
                    ):<fpage>4131</fpage>-<lpage>4140</lpage>.</mixed-citation>
            </ref>
            <ref id="B31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Ying</surname>
                            <given-names>CY</given-names>
                        </string-name>, <string-name>
                            <surname>Dominguez-Sola</surname>
                            <given-names>D</given-names>
                        </string-name>, <string-name>
                            <surname>Fabi</surname>
                            <given-names>M</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>MEF2B mutations lead to deregulated expression of the oncogene
                    BCL6 in diffuse large B cell lymphoma</article-title>. <source>Nat Immunol</source>
                    . <year>2013</year>;<volume>14</volume>(<issue>10</issue>):<fpage>1084</fpage>-<lpage>
                    1092</lpage>.</mixed-citation>
            </ref>
            <ref id="B32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Nickenig</surname>
                            <given-names>C</given-names>
                        </string-name>, <string-name>
                            <surname>Dreyling</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Hoster</surname>
                            <given-names>E</given-names>
                        </string-name>, <etal /></person-group>
                    ; <collab>German Low-Grade Lymphoma Study Group</collab>. <article-title>Combined
                    cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves
                    response rates but not survival and has lower hematologic toxicity compared with
                    combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and
                    mantle cell lymphomas: results of a prospective randomized trial of the German
                    Low-Grade Lymphoma Study Group</article-title>. <source>Cancer</source>. <year>
                    2006</year>;<volume>107</volume>(<issue>5</issue>):<fpage>1014</fpage>-<lpage>
                    1022</lpage>.</mixed-citation>
            </ref>
            <ref id="B33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Hiddemann</surname>
                            <given-names>W</given-names>
                        </string-name>, <string-name>
                            <surname>Kneba</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Dreyling</surname>
                            <given-names>M</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Frontline therapy with rituximab added to the combination of
                    cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly
                    improves the outcome for patients with advanced-stage follicular lymphoma
                    compared with therapy with CHOP alone: results of a prospective randomized study
                    of the German Low-Grade Lymphoma Study Group</article-title>. <source>Blood</source>
                    . <year>2005</year>;<volume>106</volume>(<issue>12</issue>):<fpage>3725</fpage>-<lpage>
                    3732</lpage>.</mixed-citation>
            </ref>
            <ref id="B34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Langfelder</surname>
                            <given-names>P</given-names>
                        </string-name>, <string-name>
                            <surname>Horvath</surname>
                            <given-names>S</given-names>
                        </string-name></person-group>
                    . <article-title>WGCNA: an R package for weighted correlation network analysis</article-title>
                    . <source>BMC Bioinformatics</source>. <year>2008</year>;<volume>9</volume>(<issue>
                    1</issue>):<fpage>559</fpage>.</mixed-citation>
            </ref>
            <ref id="B35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Shaffer</surname>
                            <given-names>AL</given-names>
                        </string-name>, <string-name>
                            <surname>Wright</surname>
                            <given-names>G</given-names>
                        </string-name>, <string-name>
                            <surname>Yang</surname>
                            <given-names>L</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>A library of gene expression signatures to illuminate normal
                    and pathological lymphoid biology</article-title>. <source>Immunol Rev</source>. <year>
                    2006</year>;<volume>210</volume>:<fpage>67</fpage>-<lpage>85</lpage>.</mixed-citation>
            </ref>
            <ref id="B36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Victora</surname>
                            <given-names>GD</given-names>
                        </string-name>, <string-name>
                            <surname>Dominguez-Sola</surname>
                            <given-names>D</given-names>
                        </string-name>, <string-name>
                            <surname>Holmes</surname>
                            <given-names>AB</given-names>
                        </string-name>, <string-name>
                            <surname>Deroubaix</surname>
                            <given-names>S</given-names>
                        </string-name>, <string-name>
                            <surname>Dalla-Favera</surname>
                            <given-names>R</given-names>
                        </string-name>, <string-name>
                            <surname>Nussenzweig</surname>
                            <given-names>MC</given-names>
                        </string-name></person-group>
                    . <article-title>Identification of human germinal center light and dark zone
                    cells and their relationship to human B-cell lymphomas</article-title>. <source>
                    Blood</source>. <year>2012</year>;<volume>120</volume>(<issue>11</issue>):<fpage>
                    2240</fpage>-<lpage>2248</lpage>.</mixed-citation>
            </ref>
            <ref id="B37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Gautier</surname>
                            <given-names>L</given-names>
                        </string-name>, <string-name>
                            <surname>Cope</surname>
                            <given-names>L</given-names>
                        </string-name>, <string-name>
                            <surname>Bolstad</surname>
                            <given-names>BM</given-names>
                        </string-name>, <string-name>
                            <surname>Irizarry</surname>
                            <given-names>RA</given-names>
                        </string-name></person-group>
                    . <article-title>affy--analysis of Affymetrix GeneChip data at the probe level</article-title>
                    . <source>Bioinformatics</source>. <year>2004</year>;<volume>20</volume>(<issue>
                    3</issue>):<fpage>307</fpage>-<lpage>315</lpage>.</mixed-citation>
            </ref>
            <ref id="B38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Smyth</surname>
                            <given-names>GK</given-names>
                        </string-name>, <string-name>
                            <surname>Michaud</surname>
                            <given-names>J</given-names>
                        </string-name>, <string-name>
                            <surname>Scott</surname>
                            <given-names>HS</given-names>
                        </string-name></person-group>
                    . <article-title>Use of within-array replicate spots for assessing differential
                    expression in microarray experiments</article-title>. <source>Bioinformatics</source>
                    . <year>2005</year>;<volume>21</volume>(<issue>9</issue>):<fpage>2067</fpage>-<lpage>
                    2075</lpage>.</mixed-citation>
            </ref>
            <ref id="B39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Subramanian</surname>
                            <given-names>A</given-names>
                        </string-name>, <string-name>
                            <surname>Tamayo</surname>
                            <given-names>P</given-names>
                        </string-name>, <string-name>
                            <surname>Mootha</surname>
                            <given-names>VK</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Gene set enrichment analysis: a knowledge-based approach for
                    interpreting genome-wide expression profiles</article-title>. <source>Proc Natl
                    Acad Sci USA</source>. <year>2005</year>;<volume>102</volume>(<issue>43</issue>
                    ):<fpage>15545</fpage>-<lpage>15550</lpage>.</mixed-citation>
            </ref>
            <ref id="B40">
                <label>40.</label>
                <mixed-citation publication-type="web"><collab>R Core Team</collab>. (<year>2016</year>).
                    R: A language and environment for statistical computing. R Foundation for
                    Statistical Computing, Vienna, Austria. URL <ext-link ext-link-type="uri"
                        xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link>
                    .</mixed-citation>
            </ref>
            <ref id="B41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Lenz</surname>
                            <given-names>G</given-names>
                        </string-name>, <string-name>
                            <surname>Wright</surname>
                            <given-names>GW</given-names>
                        </string-name>, <string-name>
                            <surname>Emre</surname>
                            <given-names>NCT</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Molecular subtypes of diffuse large B-cell lymphoma arise by
                    distinct genetic pathways</article-title>. <source>Proc Natl Acad Sci USA</source>
                    . <year>2008</year>;<volume>105</volume>(<issue>36</issue>):<fpage>13520</fpage>
                    -<lpage>13525</lpage>.</mixed-citation>
            </ref>
            <ref id="B42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Koues</surname>
                            <given-names>OI</given-names>
                        </string-name>, <string-name>
                            <surname>Kowalewski</surname>
                            <given-names>RA</given-names>
                        </string-name>, <string-name>
                            <surname>Chang</surname>
                            <given-names>LW</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Enhancer sequence variants and transcription-factor
                    deregulation synergize to construct pathogenic regulatory circuits in B-cell
                    lymphoma</article-title>. <source>Immunity</source>. <year>2015</year>;<volume>
                    42</volume>(<issue>1</issue>):<fpage>186</fpage>-<lpage>198</lpage>.</mixed-citation>
            </ref>
            <ref id="B43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Hu</surname>
                            <given-names>H</given-names>
                        </string-name>, <string-name>
                            <surname>Wang</surname>
                            <given-names>B</given-names>
                        </string-name>, <string-name>
                            <surname>Borde</surname>
                            <given-names>M</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Foxp1 is an essential transcriptional regulator of B cell
                    development</article-title>. <source>Nat Immunol</source>. <year>2006</year>;<volume>
                    7</volume>(<issue>8</issue>):<fpage>819</fpage>-<lpage>826</lpage>.</mixed-citation>
            </ref>
            <ref id="B44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Banham</surname>
                            <given-names>AH</given-names>
                        </string-name>, <string-name>
                            <surname>Beasley</surname>
                            <given-names>N</given-names>
                        </string-name>, <string-name>
                            <surname>Campo</surname>
                            <given-names>E</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>The FOXP1 winged helix transcription factor is a novel
                    candidate tumor suppressor gene on chromosome 3p</article-title>. <source>Cancer
                    Res</source>. <year>2001</year>;<volume>61</volume>(<issue>24</issue>):<fpage>
                    8820</fpage>-<lpage>8829</lpage>.</mixed-citation>
            </ref>
            <ref id="B45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Shaffer</surname>
                            <given-names>AL</given-names>
                        </string-name>, <string-name>
                            <surname>Rosenwald</surname>
                            <given-names>A</given-names>
                        </string-name>, <string-name>
                            <surname>Staudt</surname>
                            <given-names>LM</given-names>
                        </string-name></person-group>
                    . <article-title>Lymphoid malignancies: the dark side of B-cell differentiation</article-title>
                    . <source>Nat Rev Immunol</source>. <year>2002</year>;<volume>2</volume>(<issue>
                    12</issue>):<fpage>920</fpage>-<lpage>932</lpage>.</mixed-citation>
            </ref>
            <ref id="B46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Streubel</surname>
                            <given-names>B</given-names>
                        </string-name>, <string-name>
                            <surname>Vinatzer</surname>
                            <given-names>U</given-names>
                        </string-name>, <string-name>
                            <surname>Lamprecht</surname>
                            <given-names>A</given-names>
                        </string-name>, <string-name>
                            <surname>Raderer</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Chott</surname>
                            <given-names>A</given-names>
                        </string-name></person-group>
                    . <article-title>T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent
                    chromosomal aberration in MALT lymphoma</article-title>. <source>Leukemia</source>
                    . <year>2005</year>;<volume>19</volume>(<issue>4</issue>):<fpage>652</fpage>-<lpage>
                    658</lpage>.</mixed-citation>
            </ref>
            <ref id="B47">
                <label>47.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Banham</surname>
                            <given-names>AH</given-names>
                        </string-name>, <string-name>
                            <surname>Connors</surname>
                            <given-names>JM</given-names>
                        </string-name>, <string-name>
                            <surname>Brown</surname>
                            <given-names>PJ</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Expression of the FOXP1 transcription factor is strongly
                    associated with inferior survival in patients with diffuse large B-cell lymphoma</article-title>
                    . <source>Clin Cancer Res</source>. <year>2005</year>;<volume>11</volume>(<issue>
                    3</issue>):<fpage>1065</fpage>-<lpage>1072</lpage>.</mixed-citation>
            </ref>
            <ref id="B48">
                <label>48.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Gascoyne</surname>
                            <given-names>DM</given-names>
                        </string-name>, <string-name>
                            <surname>Banham</surname>
                            <given-names>AH</given-names>
                        </string-name></person-group>
                    . <article-title>The significance of FOXP1 in diffuse large B-cell lymphoma</article-title>
                    . <source>Leuk Lymphoma</source>. <year>2017</year>;<volume>58</volume>(<issue>5</issue>
                    ):<fpage>1037</fpage>-<lpage>1051</lpage>.</mixed-citation>
            </ref>
            <ref id="B49">
                <label>49.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Brown</surname>
                            <given-names>P</given-names>
                        </string-name>, <string-name>
                            <surname>Marafioti</surname>
                            <given-names>T</given-names>
                        </string-name>, <string-name>
                            <surname>Kusec</surname>
                            <given-names>R</given-names>
                        </string-name>, <string-name>
                            <surname>Banham</surname>
                            <given-names>AH</given-names>
                        </string-name></person-group>
                    . <article-title>The FOXP1 transcription factor is expressed in the majority of
                    follicular lymphomas but is rarely expressed in classical and lymphocyte
                    predominant Hodgkin&#x2019;s lymphoma</article-title>. <source>J Mol Histol</source>
                    . <year>2005</year>;<volume>36</volume>(<issue>4</issue>):<fpage>249</fpage>-<lpage>
                    256</lpage>.</mixed-citation>
            </ref>
            <ref id="B50">
                <label>50.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author">
                        <string-name>
                            <surname>Ballman</surname>
                            <given-names>KV</given-names>
                        </string-name>
                    </person-group>
                    . <article-title>Biomarker: Predictive or Prognostic?</article-title> <source>J
                    Clin Oncol</source>. <year>2015</year>;<volume>33</volume>(<issue>33</issue>):<fpage>
                    3968</fpage>-<lpage>3971</lpage>.</mixed-citation>
            </ref>
            <ref id="B51">
                <label>51.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Ho</surname>
                            <given-names>C</given-names>
                        </string-name>, <string-name>
                            <surname>Rodig</surname>
                            <given-names>SJ</given-names>
                        </string-name></person-group>
                    . <article-title>Immunohistochemical markers in lymphoid malignancies: Protein
                    correlates of molecular alterations</article-title>. <source>Semin Diagn Pathol</source>
                    . <year>2015</year>;<volume>32</volume>(<issue>5</issue>):<fpage>381</fpage>-<lpage>
                    391</lpage>.</mixed-citation>
            </ref>
            <ref id="B52">
                <label>52.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author">
                        <string-name>
                            <surname>Scott</surname>
                            <given-names>DW</given-names>
                        </string-name>
                    </person-group>
                    . <article-title>Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays
                    Ready for the Clinic?</article-title> <source>Am Soc Clin Oncol Educ Book</source>
                    . <year>2015</year>;<volume>35</volume>:<fpage>e458</fpage>-<lpage>e466</lpage>.</mixed-citation>
            </ref>
            <ref id="B53">
                <label>53.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Wlodarska</surname>
                            <given-names>I</given-names>
                        </string-name>, <string-name>
                            <surname>Veyt</surname>
                            <given-names>E</given-names>
                        </string-name>, <string-name>
                            <surname>De Paepe</surname>
                            <given-names>P</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>FOXP1, a gene highly expressed in a subset of diffuse large
                    B-cell lymphoma, is recurrently targeted by genomic aberrations</article-title>. <source>
                    Leukemia</source>. <year>2005</year>;<volume>19</volume>(<issue>8</issue>):<fpage>
                    1299</fpage>-<lpage>1305</lpage>.</mixed-citation>
            </ref>
            <ref id="B54">
                <label>54.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Rouhigharabaei</surname>
                            <given-names>L</given-names>
                        </string-name>, <string-name>
                            <surname>Finalet Ferreiro</surname>
                            <given-names>J</given-names>
                        </string-name>, <string-name>
                            <surname>Tousseyn</surname>
                            <given-names>T</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>Non-IG aberrations of FOXP1 in B-cell malignancies lead to an
                    aberrant expression of N-truncated isoforms of FOXP1</article-title>. <source>PLoS
                    One</source>. <year>2014</year>;<volume>9</volume>(<issue>1</issue>):<fpage>
                    e85851</fpage>.</mixed-citation>
            </ref>
            <ref id="B55">
                <label>55.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Rao</surname>
                            <given-names>DS</given-names>
                        </string-name>, <string-name>
                            <surname>O&#x2019;Connell</surname>
                            <given-names>RM</given-names>
                        </string-name>, <string-name>
                            <surname>Chaudhuri</surname>
                            <given-names>AA</given-names>
                        </string-name>, <string-name>
                            <surname>Garcia-Flores</surname>
                            <given-names>Y</given-names>
                        </string-name>, <string-name>
                            <surname>Geiger</surname>
                            <given-names>TL</given-names>
                        </string-name>, <string-name>
                            <surname>Baltimore</surname>
                            <given-names>D</given-names>
                        </string-name></person-group>
                    . <article-title>MicroRNA-34a perturbs B lymphocyte development by repressing
                    the forkhead box transcription factor Foxp1</article-title>. <source>Immunity</source>
                    . <year>2010</year>;<volume>33</volume>(<issue>1</issue>):<fpage>48</fpage>-<lpage>
                    59</lpage>.</mixed-citation>
            </ref>
            <ref id="B56">
                <label>56.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Tan</surname>
                            <given-names>LP</given-names>
                        </string-name>, <string-name>
                            <surname>Wang</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Robertus</surname>
                            <given-names>J-L</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>miRNA profiling of B-cell subsets: specific miRNA profile for
                    germinal center B cells with variation between centroblasts and centrocytes</article-title>
                    . <source>Lab Invest</source>. <year>2009</year>;<volume>89</volume>(<issue>6</issue>
                    ):<fpage>708</fpage>-<lpage>716</lpage>.</mixed-citation>
            </ref>
            <ref id="B57">
                <label>57.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Mraz</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Chen</surname>
                            <given-names>L</given-names>
                        </string-name>, <string-name>
                            <surname>Rassenti</surname>
                            <given-names>LZ</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>miR-150 influences B-cell receptor signaling in chronic
                    lymphocytic leukemia by regulating expression of GAB1 and FOXP1</article-title>. <source>
                    Blood</source>. <year>2014</year>;<volume>124</volume>(<issue>1</issue>):<fpage>
                    84</fpage>-<lpage>95</lpage>.</mixed-citation>
            </ref>
            <ref id="B58">
                <label>58.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>van Keimpema</surname>
                            <given-names>M</given-names>
                        </string-name>, <string-name>
                            <surname>Gr&#xfc;neberg</surname>
                            <given-names>LJ</given-names>
                        </string-name>, <string-name>
                            <surname>Mokry</surname>
                            <given-names>M</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>FOXP1 directly represses transcription of proapoptotic genes
                    and cooperates with NF-&#x3ba;B to promote survival of human B cells</article-title>
                    . <source>Blood</source>. <year>2014</year>;<volume>124</volume>(<issue>23</issue>
                    ):<fpage>3431</fpage>-<lpage>3440</lpage>.</mixed-citation>
            </ref>
            <ref id="B59">
                <label>59.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Walker</surname>
                            <given-names>MP</given-names>
                        </string-name>, <string-name>
                            <surname>Stopford</surname>
                            <given-names>CM</given-names>
                        </string-name>, <string-name>
                            <surname>Cederlund</surname>
                            <given-names>M</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>FOXP1 potentiates Wnt/&#x3b2;-catenin signaling in diffuse
                    large B cell lymphoma</article-title>. <source>Sci Signal</source>. <year>2015</year>
                    ;<volume>8</volume>(<issue>362</issue>):<fpage>ra12</fpage>.</mixed-citation>
            </ref>
            <ref id="B60">
                <label>60.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Brown</surname>
                            <given-names>PJ</given-names>
                        </string-name>, <string-name>
                            <surname>Wong</surname>
                            <given-names>KK</given-names>
                        </string-name>, <string-name>
                            <surname>Felce</surname>
                            <given-names>SL</given-names>
                        </string-name>, <etal /></person-group>
                    . <article-title>FOXP1 suppresses immune response signatures and MHC class II
                    expression in activated B-cell-like diffuse large B-cell lymphomas</article-title>
                    . <source>Leukemia</source>. <year>2016</year>;<volume>30</volume>(<issue>3</issue>
                    ):<fpage>605</fpage>-<lpage>616</lpage>.</mixed-citation>
            </ref>
            <ref id="B61">
                <label>61.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name>
                            <surname>Dekker</surname>
                            <given-names>JD</given-names>
                        </string-name>, <string-name>
                            <surname>Park</surname>
                            <given-names>D</given-names>
                        </string-name>, <string-name>
                            <surname>Shaffer</surname>
                            <given-names>AL</given-names>
                            <suffix>III</suffix>
                        </string-name>, <etal /></person-group>
                    . <article-title>Subtype-specific addiction of the activated B-cell subset of
                    diffuse large B-cell lymphoma to FOXP1</article-title>. <source>Proc Natl Acad
                    Sci USA</source>. <year>2016</year>;<volume>113</volume>(<issue>5</issue>):<fpage>
                    E577</fpage>-<lpage>E586</lpage>.</mixed-citation>
            </ref>
        </ref-list>
    </back><!--LRH:
    MOTTOK et al--><!--RRH:
    FOXP1 EXPRESSION IN FOLLICULAR LYMPHOMA-->
</article>